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2. Introduction 
The earliest evidence of humans using herbs or plants for therapeutic purposes comes from 
the Neanderthals (Herbs2000.com 2011, Neanderthal 2011). Over 50,000 years ago, the 
Neanderthals would use herbs and natural substances to kill the bacteria in wounds 
(Herbs2000.com 2011). 
During ancient times more than 3,000 years ago, the Egyptians, the Chinese, and 
Indians of Central America would use herbs or certain organisms like molds to stop the 
growth of harmful bacteria (Experiment-resources 2011). It was then that the discovery was 
made that molds could treat infections. This was the birth of antibiotics. However, at that time 
they did not understand how the mold could cure infections (Experiment-resources 2011). 
Later on, scientists began to search for drugs that would kill the infection-causing 
bacteria (Experiment-resources 2011).  In 1899, the two German physicians Rudolf Emmerich 
and Oscar Low, were the first to make a medication from microbes. This was the first 
antibiotic to be used in hospitals (What Is The History Of Antibiotics? 2011).  
 
From the early twentieth century, the scientists have discovered and developed many new 
antibiotics (Herbs2000.com). In 1929, the Scottish pharmacologist Sir Alexander Fleming 
discovered that molds have very good antibacterial properties. He named the 
mold Penicillium, and the chemical produced by the mold was named penicillin 
(Herbs2000.com 2011, Experiment-resources 2011). In 1935, the German pathologist and 
bacteriologist Gerhard Domagk discovered synthetic antimicrobial chemicals, which he called 
sulfonamides. During 1940’s and 50’s streptomycin, tetracycline and chloramphenicol were 
discovered (Herbs2000.com 2011). 
Since the first discovery of penicillins, antibiotics have attracted much clinical and 
pharmacological research, in response to the progressive challenges posted by bacterial 
infections; identification of new pathogens, the development of resistances to antibiotics, and 
the discovery of new diseases. Bacterial infections are common in dental practice, and 
antibiotics have therefore been used extensively in dentistry for the management of orofacial 
infections (Ellison 2009). 
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3. Antimicrobial agents and odontogenic diseases 
 
3.1 Antimicrobial therapy and periodontal diseases 
 
Periodontal pathogens 
Periodontitis is an inflammatory disease characterized by loss of attachment around the teeth 
(Lindhe et al. 2003). The importance of meticulous instruction in oral hygiene and mechanical 
debridement (scaling and root planing) in combating the pathogenic microflora in periodontal 
diseases has been stated in several studies (Lindhe et al. 2003). Most forms of periodontal 
disease can be successfully treated by a regimen that includes the institution of careful self 
performed plaque control and mechanical removal of the supra- and subgingival bacterial 
deposits (Lindhe et al. 2003). In advanced cases, however, surgical procedures are often 
performed to make the root surfaces of the teeth more accessible to debridement (Preus & 
Laurell 2003).  
While this approach usually arrests periodontal attachment loss in most patients, 
periodontal breakdown continues in some individuals despite careful treatment. These forms 
of periodontitis may involve specific pathogens which cannot be eliminated by mechanical 
therapy only (Lindhe et al. 2003). The unsuccessful treatment outcome may therefore be due 
to persistent infection by invasive subgingival bacteria (Lindhe
 
et al. 2003). For example, the 
periodontal pathogens A. actinomycetemcomitans and P. gingivalis can resist debridement and 
evade the host response by invading epithelial cells lining the gingival crevice (Burrell & 
Walters 2008). Studies have also showed that scaling and root planing alone or surgery alone 
often fail to suppress A. actinomycetemcomitans below detectable levels (Christersson et al. 
1985, Renvert et al. 1990, Slots & Rosling 1983, Slots & Listgarten 1988). 
 
Why use antibiotic when combating periodontal diseases? 
There is considerable evidence that periodontal disease is an opportunistic infection that is 
mediated by host response to an overgrowth of mostly anaerobic species within the dental 
plaque (Loesche et al. 1999).  
According to some authors, antibiotics should be used as an adjunct to refractory 
periodontal disease, advanced periodontitis, rapidly progressing periodontitis and acute 
periodontal abscess (Preus & Laurell 2003). These types of periodontal diseases represent 
complex diseases associated with specific bacterial species and specific genetic determinants 
affecting its pathogenesis, the hosts defense, and thereby the therapy outcomes (Albandar & 
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Rams 2002, Kinane & Hart 2003, Trevilatto et al. 2002). Potential periodontal pathogens 
include Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella 
intermedia, Bacteroides forsythus, Peptostreptococcus spp., Campylobacter spp., Eikonella 
corrodens, Fusobacterium nucleatum, Eubacterium spp., Treponema denticola, a variety of 
enteric rods and pseudomonads, enterococci, staphylococci and possibly yeasts (von Konow 
& Nord 1983, Lindhe et al. 2003). One approach for eliminating these pathogens is to target 
them with antibiotics (Burrell & Walters 2008). Several authors have recommended that 
periodontal diseases should be treated with adjunctive antimicrobial therapy, if they are 
associated with A.actinomycetemcomitans (de Graaff et al. 1989, Slots & Listgarten 1988, 
Slots & Rams 1990, van Winkelhoff et al. 1989).  
Other arguments in favor of combining mechanical debridement with antimicrobial 
therapy are that studies now show significant clinical benefits of antibiotics. Studies indicate 
that the addition of antimicrobial agents to mechanical debridement may reduce the need for 
further treatment, like periodontal surgery. Mechanical therapy has unwanted effects as well, 
particularly when performed repeatedly; it can damage hard tissues and produce gingival 
recessions. 
The evidence raises the possibility that many forms of periodontal disease can be 
treated with additional antimicrobial agents directed against the responsible microorganisms.  
 
Results from studies on the use of different antibiotics in treating periodontal diseases 
 
Penicillin 
Treatment outcomes in periodontal disease have traditionally been measured as an arrest in 
periodontal attachment lost (Lindhe et al. 2003). In some cases we can also see a reduction in 
probing depths and gain in attachment. We know that mechanical treatment does not 
eliminate all bacteria from diseased sites completely, and therefore additional antimicrobial 
therapy is sometimes indicated. Still, a restrictive attitude towards using antibiotics has been 
recommended, mainly to limit the development of microbial antibiotic resistance in general, 
and to avoid the risk of unwanted effects of antibiotics. 
 
All penicillins are β -lactam antibiotics and they interfere with the synthesis of the bacterial 
cell wall peptidoglycan (Felleskatalogen
 
2011, Rang & Dale 2007, Penicillin 2011). 
Penicillins are bactericidal and small-spectrum antibiotics, and they are used in the treatment 
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of bacterial infections caused by susceptible, usually Gram-positive, organisms 
(Felleskatalogen 2011, Rang & Dale 2007, Penicillin 2011).  
Although several antibiotics, such as metronidazole, azithromycin, and β-lactam 
antibiotics combined with β-lactamase inhibitors, are still generally active against pigmented 
Prevotella species (Wexler et al. 1997), resistance to penicillins is increasing (Walker 1996). 
In fact, penicillin resistance due to β-lactamase production is common in pigmented 
Prevotella species (Appelbaum et al. 1990, Jousimies-Somer et al. 1993, Kinder et al. 1986, 
Könönen et al. 1997, van Winkelhoff et al. 1997).  
The various frequencies of β-lactamase production of P.intermedia group isolates may 
be explained by differences in the geographic locations (Appelbaum et al. 1990). 
Many investigators have reported β-lactamase production in subgingival periodontal isolates 
in several countries (Bernal et al. 1998, Dubreuil et al. 2003, Fosse et al. 2002, Herrera et al. 
2000, Maestre et al. 2007, van Winkelhoff et al. 1997). Herrera et al. (2000) reported a higher 
prevalence and a more complex β-lactamase producing microflora in a group of Spanish 
patients. Handal et al. (2003) showed that β-lactamase activity in subgingival bacteria from 
refractory periodontitis in Norwegian patients also is a common feature. Eick et al. (1999) 
found that nine species from subgingival plaque samples, among them four P.intermedia and 
two P.gingivalis strains produced a β-lactamase. 
 
In a study conducted by Milazzo (2002), β-lactamase production was demonstrated in 
B.forsythus, Prevotella spp. and in F.nucleatum. Mättö et al. (1999) investigated the β-
lactamase production of P.intermedia, P.nigrescens and P.pallens isolates and their in vitro 
susceptibilities to 6 antimicrobial agents. The results in the present study showed that β-
lactamase production was common among the above mentioned species. The authors 
concluded that therapy with penicillin may not be optimal in infections involving 
P.intermedia, because of the enzymatic hydrolysis of penicillin due to the β-lactamase 
production of these species.  
Today many bacterial species produce β-lactamases (Heimdahl et al. 1981). Therefore 
penicillin cannot be recommended for empirical antimicrobial therapy when treating 
periodontal diseases.  
 
Tetracycline 
Tetracyclines are bacteriostatic agents that bind to the 30S subunit of the bacterial ribosome 
inhibiting protein synthesis (Rang & Dale 2007). They are broad-spectrum antibiotics with 
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activity against aerobic and anaerobic gram-positive and gram-negative organisms 
(Felleskatalogen
 
2011, Rang & Dale 2007). Numerous clinical and microbiological studies 
have reported that patients with periodontal diseases show significant improvement in clinical 
treatment outcomes with 1 g systemically administered tetracycline for 14 days as an adjunct 
to scaling and root planing (Christersson & Zambon 1993, Genco et al. 1981, Gjermo 1986, 
Kornman & Robertson 1985, Lindhe & Liljenberg 1984, Slots & Rosling 1983). The 
favorable results achieved by adjunctive systemic tetracycline in patients with generalized 
juvenile periodontitis are attributed to the suppression of subgingival 
A.actinomycetemcomitans (Slots & Rams 1990, Walker et al. 1985).  
 
Tetracyclines and their antimicrobial properties have long been recognized as useful adjuncts 
in the treatment of periodontal diseases. These agents are now also recognized to have non-
antimicrobial properties that may also be therapeutically advantageous (Golub et al. 1991). 
Tetracyclines have been found to inhibit host collagenase activity; an effect that would be 
expected to inhibit the connective tissue degeneration, including bone resorption (Golub et al. 
1984). These finding have been confirmed recently by Golub et al. (2010). 
 Some authors suggest that when tetracyclines are used against A.a, 3 weeks of 
treatment is desirable (Preus & Laurell 2003). Preus & Laurell (2003) underscores that 
tetracycline should only be used where other antimicrobial agents cannot be used for different 
reasons, because tetracyclines are the antibiotics to which bacteria develop resistance to the 
fastest. 
 Although systemic tetracycline as adjunct to scaling and root planing is able to 
improve treatment outcomes in many cases, other studies have showed that this therapy fails 
to eliminate A.actinomycetemcomitans from subgingival areas (Christersson & Zambon 1993, 
Mandell et al. 1986, Mandell & Socransky 1988, Slots & Rosling 1983, van Winkelhoff et al. 
1989, van Winkelhoff et al. 1992).  
The reason might be that tetracycline occurs in serum and gingival connective tissues 
in levels too low to inhibit A.actinomycetemcomitans with its properties to invade tissues (van 
Winkelhoff et al. 1989). Another reason could be because of the frequent use of tetracyclines 
in periodontal practice (Preus et al. 1992, Slots & Rams 1990). As a result of this, patients 
with refractory periodontitis often present with a history of tetracycline therapy and a 
microflora that is resistant to this antibiotic (Olsvik & Tenover 1993, Walker et al. 1993, 
Walker et al. 1996). Handal et al. (2003) found that two of the Prevotella isolates in their 
study were resistant to tetracycline. 
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 Also, some examiners have shown less effect of administration of systemic 
tetracycline. In one study, 20 individuals received scaling and root planing, with or without 
adjunctive administration of systemic doxycycline (Feres et al. 1999). Feres et al. could not 
find significant difference between the two groups.  
In another study comparing different antibiotics, doxycycline (200 mg x 1/d for 8 
days), metronidazole (500 mg x 2/d for 8 days), clindamycin (150 mg x 4/d for 8 days) or 
none, doxycycline was found to be the antibiotic with inferior effect (Sigusch et al. 2001).  
Xajigeorgiou et al. (2006) also compared different antibiotics. Metronidazole plus 
amoxicillin, doxycycline and metronidazole were studied in patients with generalized 
aggressive periodontitis. The investigators could not find any difference between the 
individuals who received adjunctive doxycycline compared to control group only treated with 
scaling and root planing (Xajigeorgiou et al. 2006).  
 
Clindamycin 
Clindamycin is a semi-synthetic lincosamide antibioticum (Rang & Dale 2007, Clindamycin 
2011). It is a bacterial protein synthesis inhibitor by inhibiting ribosomal translocation 
(Felleskatalogen 2011, Rang & Dale 2007). It does so by binding to the 50S rRNA of the 
large bacterial ribosome subunit (Felleskatalogen 2011). Clindamycin is used primarily to 
treat infections caused by susceptible anaerobic bacteria and Gram-positive cocci, and has 
a bacteriostatic effect on the targeted organisms (Felleskatalogen 2011).  
 
Clindamycin is frequently used in dentistry. Positive effects of clindamycin are the ability to 
penetrate into bone and the negative influence on the formation of biofilms (Eick et al. 2000, 
Lewis et al. 1995). Beside its bacteriostatic effect, clindamycin can interact directly with cells 
of the immune system. This was confirmed in a study performed by Eick et al. (2000). The 
purpose of the study was to determine the effect of clindamycin on the phagocyting properties 
of gingival crevicular PMNs obtained from patients with rapidly progressive periodontitis. An 
enhancement of the intracellular killing of P.gingivalis and A.actinomycetemcomitans after 
the addition of clindamycin was found in the control group (Eick et al. 2000). 
Eick et al. (2000) suggest that clindamycin therapy therefore is an effective means of 
treating periodontal disease due to obligate anaerobic bacilli such as P.gingivalis and 
P.intermedia. These species are sufficiently susceptible to clindamycin. Handal et al. (2004) 
observed 100 % susceptibility to clindamycin in all Prevotella isolates. 
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With that being said, Eick et al. (2000) could not however, show any enhancement in 
bactericidal activity of crevicular PMNs from periodontitis patients (the test group). 
Also, E.corrodens and A.actinomycetemcomitans, both important species in cases of 
periodontitis, have a natural resistance to clindamycin (Eick et al. 1999). In addition, there 
have been reports on taste disorders and other adverse effects associated with the use of oral 
clindamycin (de Groot & van Puijenbroek 2007). According to de Groot & van Puijenbroek 
2007 (2007), taste disorders associated with the use of clindamycin can be a primary effect of 
the chemical compound or a secondary effect due to disturbances in oropharyngeal microflora 
resulting from its pharmacological action. 
 
Macrolides 
Macrolides are protein synthesis inhibitors (Macrolides 2011). The mechanism of action of 
macrolides is inhibition of bacterial protein biosynthesis. They do so by binding reversibly to 
the P site on the subunit 50S of the bacterial ribosome. This action is mainly bacteriostatic, 
but can also be bactericidal in high concentrations (Felleskatalogen 2011).  
 Burrell & Walters (2008) studied the distribution of systemic clarithromycin to 
gingiva. Clarithromycin is a macrolide, and possesses a broad antimicrobial spectrum, 
favorable tissue distribution, and a low incidence of adverse effects (Rang & Dale 2007). 
Clarithromycin also readily penetrates cells to gain access to intracellular pathogens (Burrell 
& Walters 2008). The results from this study showed that clarithromycin can reach 
significantly higher concentrations in gingival tissue than in serum, and reaches higher levels 
in inflamed gingiva than in healthy gingiva (Burrell & Walters 2008). This is because 
clarithromycin accumulates in phagocytes, monocytes, fibroblasts, polymorphonuclear cells, 
macrophages and lymphocytes (Burrell & Walters 2008).  
 
Another antimicrobial agent similar to clarithromycin is azithromycin, which also is a 
macrolide. This antimicrobial agent has similar properties as clarithromycin, in the way that 
the drug is taken up by neutrophils, macrophages and fibroblasts, and is slowly released by 
these cells (Hirsch et al. 2010). Azithromycin has a potent antibiotic activity against Gram-
negative bacteria, is able to penetrate dental biofilm and has a good periodontal tissue 
penetration. Other positive properties with this agent are that when administered systemically, 
azithromycin is concentrated in the periodontal tissues where it is retained for at least 14 days 
(Hirsch et al. 2010).  
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Azithromycin has also been tested as an adjunct to scaling and root planing in the 
treatment of adult periodontitis, in a double-blind, placebo-controlled study (Sefton et al. 
1996). In this study, the azithromycin group showed better clinical and microbiological results 
than the placebo (Sefton et al. 1996). 
 
 
Fluoroquinolones  
Fluoroquinolones are bactericidal and they eradicate bacteria by directly inhibit DNA 
synthesis (Felleskatalogen 2011, Quinolone 2011). Established antibiotics such as some of the 
above mentioned agents are often not effective enough or show potential for side effects. 
Therefore, other antimicrobial agents without these disadvantages have also been 
investigated. Tanner et al. (1994) suggested that the requirements for a good antibiotic could 
be fulfilled by fluoroquinolones which are effective against the Pasteurellaeae family to 
which A. actinomycetemcomitans belongs.   
 
Kleinfelder et al. (2000) investigated the effect of systemic therapy with ofloxacin as adjunct 
to open flap surgery in patients with A. actinomycetemcomitans-associated periodontitis. 
Ofloxacin was selected from the group of the fluoroquinolones since it showed marked in 
vitro antibacterial activity against A. actinomycetemcomitans (Kleinfelder et al. 2000). 
Furthermore, the uptake of ofloxacin by resting PMNs appears to be much higher than the 
uptake of other quinolones (Walters et al. 1999). PMNs may serve as vehicles for transport 
from the bloodstream to infection sites. By this mechanism, PMNs have the potential to 
enhance resolution of an infection by increasing the local quinolone concentration at sites 
most beneficial to the host (Loo et al. 1997). 
 In the study conducted by Kleinfelder et al. (2000), 25 periodontitis patients with 
subgingival detection of A. actinomycetemcomitans were treated with ofloxacin 2 x 200 
mg/day for 5 days as adjunct to open flap surgery. Another 10 patients in the control group 
received only flap surgery. The systemic use of ofloxacin as an adjunct to periodontal flap 
surgery resulted in a significant reduction of probing depth and in a significant gain of clinical 
attachment in periodontitis patients harboring A. actinomycetemcomitans (Kleinfelder et al. 
2000). Hence, according to Kleinfelder, systemic use of ofloxacin as an adjunct to 
conventional periodontal therapy might be a valuable alternative for treatment of   
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A. actinomycetemcomitans-associated periodontitis in patients with intolerance to other 
recommended antibiotics. 
 Milazzo et al. (2002) compared the in vitro activity of moxifloxacin with that of 
penicillin, amoxicillin/clavulanate, cefoxitin, erythromycin, clindamycin and metronidazole 
against isolates associated with periodontal infections. Moxifloxacin is a relatively new oral 
quinolone with a wide spectrum of activity. Milazzo et al. (2002) concluded that moxifloxacin 
has good antibacterial activity against periodontal pathogens comparable with that of cefoxitin 
and amoxicillin/clavulanate, and better than that of clindamycin, metronidazole and penicillin. 
 Other authors have a more restricted attitude towards recommending fluoroquinolones 
when treating periodontal diseases. Preus & Laurell (2003) proposes that ciprofloxacin is 
indicated only when microbiological tests can confirm that a super infection with bacteria like 
enterobacteria, pseudomonads or staphylococci is present. If this is the case, Preus & Laurell 
recommend ciprofloxacin 500 mg x 2 per day in 10-14 days. They also underscore the 
importance of mechanical treatment and the use of clorhexidine gel, as a first attempt to 
eliminate the super infection.   
   
Metronidazole 
Metronidazole is a nitroimidazole antibiotic with bactericidal effect (Felleskatalogen 2011, 
Metronidazole 2011).  Metronidazole, taken up by diffusion, is transformed to active 
metabolites that inhibit DNA-synthesis in microorganisms (Felleskatalogen 2011). 
 Metronidazole is well absorbed when administered via the systemic route (Ings et al. 
1975), and has been shown to have a pronounced effect on the subgingival microbiota of 
periodontal lesions in both humans (Loesche et al. 1981) and dogs (Listgarten et al. 1979).  
The compound is bactericidal against the anaerobic microorganisms of the subgingival 
microflora, while large portions of aerobic and facultative anaerobic species are less sensitive 
(Metronidazole 2011).  
 Metronidazole interacts with electron transport proteins in anaerobic microorganisms 
to form derivates which interfere with the normal function of such cells (Müller et al. 1977).  
Therefore, if the infection is caused by Gram-negative anaerobes, the use of metronidazole 
might be helpful (Eick et al. 1999). Preus & Laurell (2003) suggest that 1250-1500 mg 
metronidazole per day for 10 days is effective in the treatment of periodontal diseases 
associated with P. gingivalis and P. intermedia. 
 Loesche et al. (1981) used metronidazole in the treatment of 5 patients with 
periodontal diseases. The agent was administered in tablet form (3 x 250 mg/day) for 7 days 
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and was found to have a marked and prolonged effect on the proportion of subgingival 
microorganisms as well as on some clinical symptoms characteristic of periodontal disease. 
Similar findings have been reported from experiments in dogs (Heijl & Lindhe 1980, Dahlén 
et al. 1982).  
Loesche et al. (1982) also investigated the use of metronidazole in the treatment of 
patients with acute necrotizing ulcerative gingivitis. The results showed that metronidazole 
treatment caused a rapid resolution of the clinical symptoms, which coincided with a 
significant reduction in the plaque proportions.  
 Lindhe et al. (1983) conducted a study, where 16 individuals were randomly 
distributed into two treatment groups. The patients of the test group received metronidazole 
for 3 periods of 2 weeks each, separated by intervals of 8 weeks. The systemic administration 
of metronidazole reduced/eliminated clinical signs of inflammatory periodontal disease, and 
the proportions of spirochetes in the subgingival microflora to very low levels (Lindhe et al. 
1983). The observations made in this study are in agreement with findings by Shinn (1965), 
Duckworth et al. (1966) and Loesche et al. (1981, 1984, 1992).  
These findings indicate that the use of systemic metronidazole leads to additional 
treatment benefits, including a reduced need for surgery, beyond that which can be achieved 
by debridement alone (Lindhe et al. 1983). Jenkens et al. (1989) reported that systemic 
metronidazole, either alone or accompanied by debridement, produced a significant clinical 
improvement after debridement alone had failed. Other investigators have shown that also 
patients with advanced and/or refractory forms of periodontal diseases respond well to 
metronidazole (Gusberti et al. 1988, Lundström et al. 1984).  
  
Collectively, these studies indicate that metronidazole is most effective when given to patients 
with high proportions of anaerobes/spirochetes in their plaques, and when combined with 
mechanical debridement. This means that if metronidazole were to be of value in the 
treatment of periodontal diseases, it should be so when strict anaerobes dominate in the 
subgingival microbiota.  
Facultative anaerobes like E. corrodens and A. actinomycetemcomitans, both 
important species in cases of periodontitis, have a natural resistance to metronidazole (Eick et 
al. 1999), and the agent is therefore not recommended as a single therapy when these 
pathogens are registered. This is one of the reasons why authors started to investigate 
combination therapy. 
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Combination therapy 
Several antimicrobial agents (e.g. tetracycline, metronidazole, amoxicillin clavulanate, 
clindamycin) have been tested for systemic use in periodontal therapy as single antibiotics 
(van Winkelhoff et al. 1996). Since the subgingival microbiota in advanced periodontal 
disease often includes species with different antimicrobial susceptibility, combining antibiotic 
therapy has been suggested (van Winkelhoff et al. 1989, van Winkelhoff et al. 1992).  
 Antimicrobial regimens that have successfully been used in patients with 
A.actinomycetemcomitans-associated periodontitis are metronidazole in combination with 
amoxicillin, in combination with amoxicillin/clavulanate or metronidazole plus ciprofloxacin 
(Goene et al. 1990, Pavicic et al. 1994). These combined antibiotic strategies as adjuncts to 
scaling and root planing or flap surgery were able to markedly suppress or eliminate A. 
actinomycetemcomitans from periodontal lesions. However, the increased potential for 
adverse reactions appears to be the major disadvantage of these combined antibiotic regimens 
(Idsöe et al. 1968, Roe 1977, Saxon et al. 1987). 
 
Metronidazole plus amoxicillin 
The rationale for the use of combination therapy in periodontitis is to reduce or even eliminate 
suspected pathogens that exist within the biofilm. Data from systemic reviews elucidated that 
the clinical outcomes of probing pocket depth, clinical attachment level change, and risk for 
additional clinical attachment level loss may benefit from combination therapy (Buchmann et 
al. 2010). Recently, these suggestions have been confirmed for systemic amoxicillin plus 
metronidazole in a randomized, placebo-controlled clinical trial (Guerrero et al. 2005).  
 A combination of metronidazole plus amoxicillin used as an adjuvant to mechanical 
periodontal therapy was also successful in the treatment of advanced and refractory 
periodontitis (Goené et al. 1990, Kornman et al. 1989, Pavicic et al. 1994, Rams & Slots 
1996, van Winkelhoff et al. 1992, Xajigeorgiou et al. 2006). It was shown that this regimen 
suppressed putative periodontal pathogens not only from the periodontal lesions but also from 
other sites in the oral cavity (Pavicic et al. 1994).  
Van Winkelhoff et al. (1989) also reported that mechanical therapy followed by the 
combination of metronidazole and amoxicillin was very effective in suppressing 
A.actinomycetemcomitans below cultivable levels in a group of 22 patients.  The findings of 
this study are in accord with the results reported by Xajigeorgiou et al. (2006). These authors 
concluded that adjunctive metronidazole plus amoxicillin is effective in aggressive 
periodontitis patients.  
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 Buchmann et al. (2010) conducted a study to investigate the short-term effects of 
nonsurgical therapy (scaling and root planing/SRP) on the subgingival microbiota in chronic 
and aggressive periodontal disease. 97 patients underwent scaling and root planing and 
received either systemic metronidazole plus amoxicillin or were treated with SRP along with 
placebo tablet. The investigators stated that nonsurgical therapy resulted in both a suppression 
and early elimination of pathogens immediately after completion of active treatment 
(Buchmann et al. 2010). 
 In another study conducted by Berglundh et al. (1998), they looked at the effect of 
systemic administration of metronidazole and amoxicillin as an adjunct to mechanical therapy 
in patients with advanced periodontal disease. 16 individuals participated and 4 different 
treatment groups were formed; group 1: antibiotic therapy but no scaling, group 2: antibiotic 
therapy plus scaling, group 3: placebo therapy but no scaling, group 4: placebo therapy plus 
scaling.  
The findings of the present clinical trial demonstrated that in patients with advanced 
periodontal disease, systemic administration of metronidazole plus amoxicillin resulted in an 
improvement of the periodontal conditions, elimination of putative periodontal pathogens 
(such as A. actinomycetemcomitans, P. gingivalis, and P. intermedia), and a reduction of the 
size of the inflammatory lesion (Berglund et al. 1998).  
The antibiotic regimen alone, however, was less effective than mechanical therapy 
with respect to reduction of BOP-positive sites, probing pocket depth reduction and probing 
attachment gain. The combined mechanical and systemic antibiotic therapy was more 
effective than mechanical therapy alone in terms of improvement of clinical and 
microbiological features of periodontal disease.  
In the non-scaled quadrants in the placebo group, there were unchanged signs of 
gingivitis and probing pocket depth, but a significant further loss of probing attachment. In 
addition, the subgingival microbiota as well as the connective tissue lesion remained 
unchanged both in terms of quantity and quality (Berglundh et al. 1998).  
 The finding that self-performed, supragingival plaque control as a single measure was 
insufficient to prevent further attachment loss, is in agreement with findings presented by 
Rosling et al. (1997). The results in this study demonstrated that in subjects with advanced 
and recurrent periodontitis, carefully practiced supragingival plaque control was insufficient 
to prevent disease progression (Rosling et al. 1997). 
 Berglund’s observation that the antibiotic regimen altered the subgingival microbiota 
is in agreement with findings by Pavicic et al. (1994). Pavicic et al. demonstrated that 
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amoxicillin enhanced the uptake of metronidazole and that this combination of antibiotics 
increased the antimicrobial range. A total of 48 subjects with A.a-associated periodontitis 
participated in this study. After the initial therapy of mechanical debridement and oral 
hygiene instructions, all patients received 250 mg x 3 metronidazole plus 375 mg x 3 
amoxicillin for 7 days.  
The results indicated that mechanical debridement followed by 
metronidazole/amoxicillin therapy is able to suppress A. actinomycetemcomitans below 
cultivable levels (Pavicic et al. 1994). Furthermore, they concluded that recurrence of A. 
actinomycetemcomitans  to detectable levels by this therapy rarely occurs.  
Preus & Laurell (2003) suggest the following combination therapy when treating A.a-
associated periodontal disease: metronidazole 750 mg per day plus amoxicillin 1250 mg per 
day for 8 days.  
 
Conclusion 
Mechanical removal of bacterial deposits on subgingival root surfaces is still the key 
intervention to treat periodontal diseases, and the use of systemic antibiotics should be 
restricted to specific groups of periodontal patients, for example those with highly active 
disease or a specific microbiological profile (Asikainen et al. 2001). The different 
susceptibilities of these pathogens to antimicrobial agents make therapy very difficult. 
Microbiological testing has thus been advocated to identify subjects that harbor these 
organisms (Finegold 1985, Mombelli 2005, Mombelli 2006, Preus & Laurell 2003).  
 It is recommend that antibiotics should be used as an adjunct to the treatment of 
aggressive and severe chronic forms of periodontitis only after subgingival debridement has 
occurred (Herrera et al. 2008). 
 Antimicrobial agents alone are unlikely to be effective in the presence of subgingival 
calculus (Slots et al. 2000). Studies show that we should quantitatively reduce the mass of 
bacteria, which otherwise may inhibit or degrade the antimicrobial agent. Second, we should 
mechanically disrupt the structured bacterial aggregates that can protect the bacteria from the 
agent. This underscores the importance of subgingival mechanical debridement.  
Also, because most periodontal pathogens are endogenous to humans, the use of 
antibiotics may result in suppression rather than elimination (Buchmann et al. 2010). 
Therefore, periodontitis patients need to be controlled regularly after the completion of the 
debridement procedures in order to avoid recurrence of the disease (Preus & Laurell 2003). 
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 Not all patients benefit equally from antibiotics because they display different 
microflora and harbor individual susceptibilities against key microbiota. Therefore, 
elimination or persistence of pathogens after antibiotic usage is an unpredictable event 
depending on the individual host-pathogen relationship. 
 
3.2 Antimicrobial therapy and odontogenic abscesses 
 
What is an abscess? 
An abscess is a localized collection of bacteria, inflammatory cells and tissue breakdown 
products, which collectively is called pus. It originates when pulpal tissues initiate an 
inflammatory response to trauma or caries and may eventually lead to pulpal necrosis 
(Matthews et al. 2003). From this point, the inflammation may become chronic or 
exacerbation can occur with the formation of a clinical abscess. The formation of pus leads to 
an increase in tissue pressure, bone resorption, and the pus outbreak through the bone 
underneath the periosteum into the tissue spaces (Chow et al. 1978, Skucaite et al. 2009).  
 Dentoalveolar abscesses consist of two main types: the endodontic (periapical) abscess 
formed after necrosis of the dental pulp, and the periodontal abscess formed after infection of 
the periodontal tissues by bacteria of the subgingival microbiota (Dahlén 2002). The 
periodontal abscess is an acute lesion, resulting in rapid destruction of tooth support structures 
(Herrera et al. 2000).  
 An abscess that only involves soft tissue is termed cellulitis. The spreading may also 
involve bone (osteitis) or the bone marrow (osteomyelitis) (Chow et al. 1978). A phlegmon 
results when an acute infection is not confined as in the case of abscess (Abscess and 
Phlegmon 2011, Flegmone 2011). Dental abscesses and abscesses in general expand through 
tissue providing least resistance by forming a sinus tract or a fistula (Dahlén & Frandsen 
2002).  
Periodontal abscesses occurring in periodontal pockets have been explained by different 
etiological theories: 
1. Exacerbation of a pre-existing periodontitis ( Fine 1994, Dello Russo 1985) 
2. Inappropriate periodontal therapy, mainly prophylaxis or scaling, which can leave 
calculus in the deeper parts of the pocket (Dello Russo 1985, Carranza 1990). 
3. Re-occurrence of super infections, after systemic antibiotic therapy (Helovuo & 
Paunio 1989, Helouvo et al. 1993, Topoll et al. 1990). 
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Microflora  
The periodontal abscess microflora is composed mainly of periodontal pathogens and is 
polymicrobial, especially P. gingivalis, P. intermedia, F. nucleatum, B. forsythus and P. 
micros (Baker & Fotos 1994, Betsy et al. 1983, Brook 1991, Gill & Scully 1990, Heimdahl & 
Nord 1985, Herrera et al. 2000, Khemaleelakul et al. 2002, Kuriyama et al. 2000, Kuriyama et 
al. 2002, Kuriyama et al. 2006, Lewis et al. 1995, MacFarlane et al. 1990, Meng et al. 1999, 
Moenning et al. 1989, Newman et al. 1979, Shira et al. 1980, Takai et al. 2005, Topoll et al. 
1990, Vigil et al. 1997). 
Herrera et al. (2000) conducted a study where the purpose of the study was to investigate the 
prevalence of pathogens in periodontal abscesses (Fig. 1). The results were as following: 
 
 
 
Figure 1. Prevalence of each studied pathogen in periodontal abscess (Herrera et al. 2000) 
 
A.a. = A. actinomycetemcomitans  P.m.=  P. micros 
P.g. = P. gingivalis    C.r. = C. rectus 
P.i. = P. intermedia    F.n. = F. nucleatum 
B.f. = B. forsythus    P.mel.= P. melaninogenica 
 
According to Brook (2002), the main anaerobes are pigmented Prevotella and 
Porphyromonas, Fusobacterium spp. and Peptostreptococcus spp. The most commonly 
isolated aerobes and facultative bacteria are Streptococcus pyogenes and Staphylococcus 
aureus. Külekci et al. (1996) investigated aspirates of pus from dentoalveolar abscesses, and 
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presented the same results as Brook (2002), with Prevotella spp., Peptostreptococcus spp. and 
Streptococcus spp. being the predominant isolates. 
The bacteriological data reported by Kuriyama et al. (2000) are in agreement with 
these studies. Kuriyama et al. reported that a mixed infection of strict anaerobes with 
facultative anaerobes was observed most often in dentoalveolar infections. 
Lewis et al. (1990) also showed similar results; the microflora is predominately 
involving CO2-dependent streptococci, strictly anaerobic Gram-positive cocci and strictly 
anaerobic Gram-negative bacilli. Newman & Sims (1979) found that 63.1 % of the flora was 
strict anaerobes. Topoll et al. (1990) reported 59.5 % of strict anaerobes, whereas Herrera et 
al. (2000) calculated 45.1%.   
In conclusion, it is generally accepted that the microflora of acute dental abscesses is usually 
polymicrobial with a predominance of strict anaerobes. Only with an understanding of the 
oral environment, the organisms, and their synergistic existence, can intelligent antibiotic 
choices be made for the treatment of odontogenic infections (Moenning et al.1989). 
 
Treatment of abscesses 
Most dentoalveolar infections arise from overgrowth of normal commensals within the oral 
cavity as a result of changes in local environmental conditions, leading to opportunistic 
infections (Ellison 2009). As mentioned above, Dentoalveolar infections are not caused by a 
single microorganism but are mixed infections, and there is a progression of the microbial 
species as the infection develops reflecting ecological changes in the affected site (Dirks & 
Terezhalmy 2004, Marsh & Martin 1999, Pallasch et al. 1993).  
Mechanical removal of necrotic infected tissues and surgical drainage are the most 
important treatment steps (Chow et al. 1978). Some authors restrict the use of antibiotics to 
specific situations, such as systemic involvement (Ahl et al. 1986), need of premedication, 
diffuse infection, and difficulties to achieve drainage (Lewis et al. 1987).  
Antibiotic therapy is generally indicated in case of systemic symptoms and to limit the spread 
of the infection (Dahlén 2002, Epstein & Scopp 1977). For example, bacterial metabolites, 
along with endotoxins and exotoxins, may enter the blood stream. These affect the 
thermoregulatory centre in the hypothalamus leading to an increased body temperature 
(Ellison 2009). 
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 Drainage of an abscess allow the release of  pus, reduce the overall number of 
microorganisms, decrease the tissue pH, increase oxygen diffusion and allow antibiotics to 
penetrate (Ellison 2009). This is followed by removal of the cause of the infection, which 
include proper endodontic treatment, and adjunctive antibiotic therapy if needed. In 
circumstances where adequate drainage cannot be achieved, the role of antibiotic therapy is of 
even greater significance (Kuriyama et al. 2005, Kuriyama et al. 2007). 
Systemic antibiotic therapy prevents the infection from spreading and it acts in places 
that mechanical treatment cannot reach (Dahlén & Frandsen 2002, López-Píriz et al. 2007). 
For the antibiotic to be successful in overcoming the associated systemic symptoms, it must 
be active against the microorganisms present, be sensitive to those bacteria and be given in 
adequate dose, frequency and duration to aid resolution of the systemic symptoms (Brook & 
Foote 2005, Ellison 2009).  
 
Results from studies on the use of different antibiotics in treating odontogenic abscesses  
 
Penicillin 
All penicillins are β-lactam antibiotics and are used in the treatment of bacterial infections 
caused by susceptible, usually Gram-positive, organisms (Felleskatalogen 2011). 
Among the systemic antibiotics employed in the treatment of acute abscesses, penicillin is by 
far the most common (Genco 1991, Gill & Scully 1988, Gilmore et al. 1988, Lewis et al. 
1989, Warnke et al. 2008). This is because of its historical effectiveness, minimal toxicity, 
and relatively low cost (Moenning 1989). Phenoxymethylpenicillin (250 mg 6 hourly) has 
traditionally been regarded as the antimicrobial therapy of choice for patients with acute 
dentoalveolar abscess (Barker et al. 1987, Gill & Scully 1988, Lewis et al. 1989), and 
erythromycin for those with a known hypersensitivity to penicillin.  
 Although the predominance of strict anaerobes in oral infections would make 
metronidazole a logical choice, S. milleri, which is resistant to metronidazole, is frequently 
isolated in the flora (Lewis et al. 1990). Therefore despite the occurrence of penicillin-
resistant anaerobes, microbiological information would support the use of penicillin.  
Baumgartner & Xia (2003) performed antibiotic susceptibility tests on a panel of 
bacteria isolated from endodontic infections. Each of the 98 species of bacteria was tested for 
antibiotic susceptibility to a panel of six antibiotics. The antibiotics were penicillin V (Pen V), 
amoxicillin (Amox), amoxicillin and clavulanic acid (Amox/Clav), clindamycin (Clin), 
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metronidazole (Met) and clarithromycin. Baumgartner & Xia (2003) found the following 
percentages of susceptibility for the 98 microbial species studied (Fig.2):  
    
Figure 2. The percentages of susceptibility for 98 species (Baumgartner & Xia 2003). 
 
The results showed that most of the root canal microbiota is susceptible to penicillins. This 
makes them the drug of choice to be used in infections of endodontic origin (Baumgartner & 
Xia 2003, Skucaite et al. 2009). 
 Fouad et al. (1996) conducted a study where the purpose of the study was to examine 
the effect of penicillin supplementation on reduction of symptoms and the course of recovery 
of localized acute apical abscess after emergency endodontic treatment. 32 patients were 
divided into three groups: (1) active group, (2) placebo group, (3) neither medication group. 
In this study however, the authors found that the administration of penicillin did not provide a 
clinically significant improvement in the course of recovery of patients with localized acute 
apical abscess, and there were no significantly differences between the three groups. The 
same results were presented by Henry et al. in 2001 and Keenan et al. in 2009. 
 Eick et al. (1999) investigated the activity of penicillin, amoxicillin, cefoxcin, 
clindamycin, doxycycline, metronidazole and ciprofloxacin. The purpose of their study was to 
determine MICs of commonly used antibiotics against oral bacteria. Compared with bacteria 
obtained from subgingival plaque samples, species isolated from odontogenic abscesses 
showed a higher resistance to the antimicrobials tested. Eick et al. also found that nine species 
from subgingival plaque samples, among them four P. intermedia and two P. gingivalis 
strains produced a β-lactamase. 
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Amoxicillin and Co-amoxiclav 
Of the penicillins, amoxicillin is particularly well absorbed, achieves high concentration at 
sites of acute infection (Boon et al. 1982, Bresco et al. 2006) and has been used successfully 
in a short course high-dose form of therapy (Lewis et al. 1986). However the basic cost of a 
standard course of amoxicillin (250 mg 8 hourly for 5 days) is approximately 10 times that of 
a standard course of penicillin. This has obviously implications when deciding on 
antimicrobial prescription policies.  
Reports showing that a high percentage of periodontal pockets and abscesses harbor  -
lactamase producing bacteria (Lewis et al. 1995, Van Winkelhoff et al. 1997, Walker et al. 
1987), have lead to the use of amoxicillin plus clavulanic acid (Lewis et al. 1993, Sobottka et 
al. 2002, Warnke et al. 2008). Amoxicillin has been widely used in Japan and the UK, largely 
because of its better absorption from the gastrointestinal tract compared with other oral 
penicillin agents (Kuriyama et al. 2005, Martin et al. 1997). 
Lewis et al. (1993) conducted a randomized, operator-blind, comparative clinical trial, 
where they studied the efficacy of co-amoxiclav and penicillin V. A total of 79 patients 
participated, and were divided into two groups. One group received 250 mg amoxicillin plus 
125 mg clavulanic acid every 8 hours in 5 days, and the other group received 250 mg 
penicillin V every 6 hours in 5 days. Symptoms improved in all patients following start of 
treatment, however those receiving co-amoxiclav recorded a significantly greater decrease in 
pain during the second and third day. Also, penicillin-resistant organisms were isolated from 5 
patients. 
 
Macrolides  
Erythromycin is regarded as the drug of choice for treatment of dental infections in patients 
with a known hypersensitivity to penicillin (Heimdahl et al. 1983, Josefsson et al. 1985, 
Lewis et al. 1995, Martin et al. 1997). However, it has been noted that erythromycin is not 
effective against anaerobes such as Fusobacterium (Kuriyama et al. 2000, Limeres et al. 
2005). Kuriyama et al. (2000) reported in a study that erythromycin had poor antimicrobial 
activity against Fusobacterium. Furthermore, erythromycin was ineffective against viridians 
streptococci.  
It has been demonstrated that Streptococcus and Fusobacterium are more frequently 
isolated from severe odontogenic infections than from milder infections (Heimdahl & Nord 
1985). The results of this study suggest that erythromycin may be effective against mild or 
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moderate infections in people with penicillin allergies, but it may not be suitable in cases of 
more severe infections or infections involving anaerobes. These recommendations are 
suggested by Kuriyama et al. (2000).  
 
Newly developed macrolides have shown better antimicrobial against gram-negative bacteria, 
than erythromycin. Among this newer generation of macrolides, azithromycin has attracted a 
lot of attention due to its pharmacokinetic properties and its high concentration in infection 
sites. Macrolides, because of their spectrum of activity and pharmacokinetic characteristics of 
high penetration into soft tissues, such as the gingiva and dental pulp, are frequently used in 
dental practice (Lo Bue et al. 1993).  
Azithromycin may have advantages in the treatment of odontogenic infections, 
because of its in-vitro and in-vivo activity against the major dental pathogens. Its 
pharmacokinetic features ensure much higher and sustained tissue concentrations compared 
with other antibiotics of the same and different classes. The uptake and transport of 
azithromycin within macrophages, and its release during bacterial phagocytosis, may augment 
the concentrations of azithromycin at the site of infection (Lo Bue et al. 1993).  
 An open, randomized clinical trial comparing the efficacy of azithromycin and 
spiramycin was conducted Lo Bue et al. (1993). 60 patients with odontogenic infections were 
randomized into two treatment regimens: 30 patients received azithromycin capsules 500 
mg/day for 3 days and the remaining 30 received spiramycin tablets 3 000 000 units per day 
for 7 days, all in conjunction with surgery. The authors concluded that there was a more rapid 
resolution of symptoms in the group treated with azithromycin. 
 Herrera et al. (2000) compared the efficacy of azithromycin to that of co-amoxiclav. 
The aim of this short-term, open parallel longitudinal clinical study was to compare the 
clinical and microbiological efficacy of two different antibiotic regimes in the treatment of 
acute periodontal abscesses. The results showed that both antibiotic regimes were effective in 
the short-term treatment of acute periodontal abscesses.  
 Clarithromycin is a macrolide and analogue of erythromycin. It has been 
recommended as an alternative to erythromycin because it is effective against facultative and 
anaerobic, which are resistant to erythromycin. In addition, food has no effect on the 
absorption of clarithromycin, and it only needs to be taken twice a day with less gastric upset 
than erythromycin.  
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Clarithromycin seems to have efficacy, but it is still considered an antibiotic under 
investigation because the minimum inhibitory concentration has not been established.  
 
Metronidazole  
Kuriyama et al. (2007) reported that metronidazole is a useful alternative in combating the 
anaerobic bacteria involved in dentoalveolar infection. Roche et al. (1997) also found 
anaerobes from odontogenic abscesses to be highly susceptible to metronidazole. The same 
results were presented by Ingham et al. (1977) and Lewis et al. (1995). Lewis et al. (1995) 
also showed that metronidazole is effective against strictly anaerobic bacteria. However, since 
the flora of acute dentoalveolar abscesses are polymicrobial, appearance of facultative 
bacteria such as S.milleri makes the use of metronidazole inappropriate in these cases (Lewis 
et al. 1995), at least as a single regimen. 
 
Clindamycin 
Clindamycin is an effective antibiotic against strict anaerobes including β-lactamase-
producing bacteria. The findings of Kuriyama et al. (2000, 2007) confirmed that clindamycin 
is effective against strict anaerobes, particularly against pigmented and nonpigmented 
Prevotella. 
Clindamycin produces high alveolar concentrations, and bacterial activity is achieved 
clinically with the usual recommended dose. In addition, clindamycin might increase host 
defense potential and inhibit β-lactamase production. Thus, clindamycin would be effective in 
the treatment of infections. However, because of its propensity to cause antibiotic-associated 
colitis, it has not been widely used in more routine cases of mild to moderate infections 
(Heimdahl & Nord 1985, Kuriyama et al. 2000, Kuriyama et al. 2007, Lewis et al. 1995, 
Limeres et al. 2005). Kuriyama et al. (2000) recommend clindamycin for the treatment of 
severe infections, or in cases in which penicillin therapy has failed. 
The efficacy of clindamycin and phenoxymethylpenicillin in the treatment of orofacial 
infections was compared in a randomized study where 60 patients participated (von Konow et 
al. 1992). 30 patients received clindamycin 150 mg every 6 h for 7 days, and 30 patients 
received phenoxymethylpenicillin 1 g every 12 h for 7 days. The authors could not find any 
statistically significant difference between the two therapy regimes.  
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Fluoroquinolones 
Moxifloxacin is a quinolone compound, which has shown good pharmacokinetic properties, 
such as high concentrations in bone tissue (Al-Nawas et al. 2009). The pharmacokinetic 
properties allow a single dose treatment per day. This reduces costs and enhances the patient’s 
compliance. Besides these promising features, its clinical effect has yet to be proven when it 
comes to treating dental abscesses, and the long-term development of the resistance situation 
should be carefully kept in mind (Al-Nawas et al. 2009). Their poor activity against anaerobes 
will limit their value in treatment of oral infections (Moenning et al.1989). 
 
Conclusion 
Understanding of the microorganisms responsible for dentoalveolar infections and their 
susceptibility to various antibiotic agents has progressed significantly. In addition, increasing 
resistance to antibiotics has led to the need for more appropriate prescribing and to review 
whether prescribing antibiotics is required at all (Ellison 2009). 
The definitive treatment of dentoalveolar abscess is drainage and removal of the cause 
of the infection. In the majority of cases this is the only treatment required (Brennan et al. 
2006). However, if the patient is showing signs of systemic illness as a result of their 
dentoalveolar infection, or are significantly immunocompromised, the adjunctive therapy with 
antibiotics may be indicated (Ellison 2009). Clinical signs of fever, trismus, significant 
regional lymphadenopathy, gross facial swelling, closure of the eye, dysphagia, tachycardia 
and rigors should be regarded as indicators of systemic response to infections and adjunctive 
therapy is always indicated (Ellison 2009). Effective drainage to reduce the number of 
bacteria, promote aerobic conditions and optimize a return to health may be the most 
important part of the process of abscess resolution (Ellison 2009).  
 Ellison describes a few guidelines in her article from 2009. Infections derived from the 
periodontal tissues are anaerobic in nature and metronidazole is the antibiotic of choice. 
Furthermore, Ellison states that infections derived from periapical tissues are mixed 
infections, but predominantly anaerobic, and are most appropriately treated with amoxicillin, 
metronidazole or clindamycin. With regards to dosage, Ellison suggests that the lowest 
possible effective dose should be used. In order to achieve sufficient concentration of 
antibiotic in the tissues, the blood concentration should exceed the MIC by a factor of four. A 
dose of 250 mg x 3/day amoxicillin, 200 mg x 3/day metronidazole or a dose of 150 mg x 
4/day clindamycin will be sufficient to achieve the required blood concentration.  
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 Other authors recommend β-lactam antibiotics as the first-line agent for the treatment 
of orofacial odontogenic infections because they work well against the specific bacterial 
causative agents of orofacial odontogenic infections with a very low incidence of adverse 
effects (Baker & Fotos 1994, Gill & Scully 1990, Heimdahl & Nord 1985, Kuriyama et al. 
2000, Moenning et al. 1989). In addition, treatment with β-lactam antibiotic is cost-effective. 
Penicillins are also among the few antibiotics that are indicated when treating odontogenic 
infections in patients that are pregnant (Sá del Fiol et al. 2005).  
 A problem with antimicrobial therapy with β-lactam antibiotics is the increasing rate 
of β-lactamase production, which leads to treatment failures (Heimdahl et al. 1980, von 
Konow et al. 1990, Lewis et al. 1995). Heimdahl & Nord (1985) and Kinder et al. (1986) have 
noted that the use of penicillin is associated with the emergence of β-lactamase producing 
bacteria. The prevalence of penicillin resistance within the flora of acute dental abscess is 
believed to be approximately 5 % (Heimdahl & Nord 1985, Lewis et al. 1989, Lewis et al. 
1993, von Konow & Nord 1983, Ranta et al. 1988). 
 Moreover, since orofacial odontogenic infections are polymicrobial (Baker & Fotos 
1994, Brook 1991, Gill & Scully 1990, Heimdahl & Nord 1985, Herrera et al. 2000, 
Kuriyama et al. 2000, Kuriyama et al. 2002, Kuriyama et al. 2006, Lewis et al. 1995, 
MacFarlane et al. 1990, Moenning et al. 1989, Newman et al. 1979, Topoll et al. 1990), the 
emergence of β-lactamase-positive bacteria may protect β-lactamase-negative bacteria from 
the β-lactam antibiotics, and thereby affect the outcome of antimicrobial therapy with β-
lactam antibiotics (Hackman & Wilkins 1976). 
 Kuriyama et al. (2000) showed in their study that there was a correlation between the 
prevalence of the isolation of β-lactamase-producing bacteria and the duration of the past 
administration of β-lactam antibiotics. They found that β-lactamase-producing bacteria were 
isolated more frequently, as the administration duration increased. The present study suggests 
that if patients with orofacial odontogenic infections have already received β-lactam 
antibiotics for three days or more, regardless of the type of antibiotic or the route of 
administration, it should be assumed that β-lactamase-producing bacteria are present in the 
lesion and are associated with infection progression (Kuriyama et al. 2000).  
Therefore, the authors recommend that the prescription of penicillins is suitable if the 
patient has not received β-lactam antibiotics in the course of the infection. If the patient has 
received antimicrobial therapy with β-lactam in the course of the infection for a duration of 3 
days or more, it should be assumed that β-lactamase-producing bacteria may occur or be 
present in the still-existing lesion. In such cases, β-lactamase-stable β-lactam antibiotics or 
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non β-lactam antibiotics such as clindamycin or macrolide are recommended (Kuriyama et al. 
2000). 
 From a clinical point of view, erythromycin, for patients known to be hypersensitive to 
penicillins, should remain antibiotic of first choice for management of acute suppurative oral 
infections (Lewis et al.1995, Sundqvist & Haapasalo 2002). On the rare occasions that 
patients fail to respond to this initial treatment, alternative antibiotics should be considered 
(Baker & Fotos 1994, Gill & Scully 1990, Heimdahl & Nord 1985, Kuriyama et al. 2000, 
Lewis et al. 1995, Moenning et al. 1989). 
 Incorrect antimicrobial use can lead to a selection of resistant bacteria species in the 
biofilm, in addition to side effects and ecological alterations in the host (López-Píriz et al. 
2007, Takahashi et al. 1998). The increasing resistance of anaerobic bacteria to some widely 
used antibiotics for treatment of oral infections ensures the need of monitoring susceptibility 
patterns (Skucaite et al. 2009).  
 
3.3 Antimicrobial therapy and osteomyelitis of the jaws 
 
What is osteomyelitis? 
Osteomyelitis can be defined as an inflammatory condition of the bone, which begins as an 
infection of the medullary cavity, rapidly involves the haversian systems, and extends to 
involve the periosteum of the affected area (Topazian et al. 1994). Bacteremia, dental 
infections, infections of the oral cavity, trauma, or surgery are the major predisposing factors 
for this infection (Malincarne et al. 2006).  
Bone necrosis and bone destruction occur early in the course of osteomyelitis, leading 
to a chronic process and eliminating the hosts ability to eradicate the pathogens. Osteomyelitis 
most commonly results from bacterial infections, although fungi, parasites, and viruses can 
affect the bone and marrow (Prasad et al. 2007). Conditions altering the vascularity of the 
bone such as radiation, malignancy, osteoporosis, osteopetrosis, and Paget’s disease can 
predispose to osteomyelitis (Prasad et al. 2007).  
 Abrupt onset of symptoms and signs during the initial stage of infection indicates an 
acute osteomyelitis. If this phase passes without complete elimination of infection, chronic 
osteomyelitis can become apparent (Prasad et al. 2007). 
Chronic osteomyelitis is a distressing bone disease often characterized by subsidence 
of systemic symptoms but with one or more foci of pus, infected granulation tissue or 
sequestra still lodged in the bone (Alonge et al. 2003, Euba et al. 2009). Chronic osteomyelitis 
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can be primary, when it arises from failed treatment of acute haematogenous osteomyelitis or 
secondary, when it is caused by trauma to the bone, open fractures or from post-operative 
infection (Bartkowski et al. 1998). 
 
Microbiology of osteomyelitis 
Alonge et al. (2003) did a study where the bacteria samples from 60 patients with chronic 
osteomyelitis were cultured. The results showed that Staphylococcus aureus is the single most 
common microorganism isolated in about 60 % of cases, but the isolate is often a mixed flora 
particularly in secondary chronic osteomyelitis. Calhoun et al. (1988), Mader et al. (1999) and 
Waldvogel et al. (1970) have also shown that the microflora in osteomyelitis is polymicrobial, 
and the organism most commonly isolated is Staphylococcus aureus. 
 
The role of antimicrobial therapy in the treatment of osteomyelitis 
Bone infections are difficult to treat, and the therapeutic success depends greatly on the 
diffusion of antibiotics into the bone tissue (Cachovan et al. 2009). Treatment of osteomyelitis 
is particularly challenging and involves adequate antimicrobial therapy and surgical 
debridement of all necrotic bone and soft tissues (Landersdorfer et al. 2009). Despite great 
advances in antimicrobial therapy, osteomyelitis in the head and neck is a difficult disease to 
treat, partly because of the anatomical region and also because of esthetic considerations 
(Fraimow 2009).  
 As bone is less vascularized tissue than for example, the lungs or skin, it is particularly 
important to investigate the bone penetration of an antibiotic before using the agent in patients 
with bone diseases. The presence of pus and ischemic regions (sequester) may further 
decrease blood circulation (Landersdorfer et al. 2009).  The composition of bone is different 
from that of other tissues, and it is difficult to predict whether agents showing good 
penetration into other tissues will also achieve high concentrations in bone (Landersdorfer et 
al. 2009).  
Antibiotics in the systemic circulation reach the capillaries in bone and, depending on 
the chemical profile and molecular size, pass through the capillary walls to enter the fluid 
space (Cachovan et al. 2009). The penetration of antibiotics into sites outside the vascular 
circulation is dependent upon factors such as serum pharmacokinetics, protein binding, lipid 
solubility, ionization state, active transport, passive diffusion, and degree of inflammatory 
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response (Daly et al. 1982, Gerding & Hitt 1989, Pinto et al. 1986, Wittmann & Schassan 
1982).  
Effective antimicrobial therapy is an essential component of most curative treatment regimens 
for osteomyelitis. In acute osteomyelitis, appropriately targeted antimicrobial therapy alone 
without other therapeutic measures may sometimes be adequate to achieve eradication of 
infecting organisms and cure of infection (Merkesteyn et al. 1997).  
However, successful management of more severe cases of acute or chronic 
osteomyelitis generally requires a combination of targeted antimicrobial therapy to eradicate 
infectious microorganisms and surgical interventions for debridement of necrotic and 
devitalized tissue, drainage of abscesses, and removal of infected bone (Chow et al. 1978, 
Fraimow 2009, Hudson 1993, Marx 1991, Topazian 1994).  
 Antimicrobial therapy is indicated when infection has perforated the cortex and has 
spread into the surrounding tissue (Isla et al. 2005). Furthermore, it is important to consider 
antimicrobial therapy if there are signs of systemic involvement. The clinical signs of 
systemic involvement are pyrexia, lymphadenopathy, difficulty in swallowing, and lockjaw 
(Dirks & Terezhalmy 2004, Jimenez et al. 2004).  
 
Results from studies on the use of different antibiotics in treating osteomyelitis 
 
Penicillin 
The antibiotics most commonly prescribed by dentists in managing odontogenic infections are 
penicillins (Sweeny et al. 2004). Despite lower bone concentrations (Darly et al. 2004, 
Summersgill et al. 1982), penicillins are effective against major pathogens and are still the 
drug of choice in uncomplicated infections (Eckert et al. 2005, Gilmore et al. 1998, Peterson 
et al. 2002). β-lactams are likely to distribute mainly within the vascular and extracellular 
fluid spaces in bone (Daly et al. 1982, Hall et al. 1983, Hughes & Anderson 1985, Lunke et 
al. 1981). Several studies have reported good results on the bone penetrating properties of 
amoxicillin and clavulanic acid (Adam et al. 1987, Akimoto et al. 1982, Grimer et al. 1986, 
Landersdorfer et al. 2009, Pignanelli et al. 1981, Weismeier et al. 1989).  
 Staphylococcus aureus remains the predominant pathogen isolated in all forms and 
stages of osteomyelitis (Pontzer & kaye 1984). Therefore, β-lactam antimicrobials remain the 
drug of choice for non-allergic patients with methicillin-susceptible Staphylococcus aureus 
(MSSA) infections (Fraimow 2009). However, less than 5 % of S. aureus is still susceptible to 
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penicillin. For such strains, intravenous penicillin G is used at doses of 3 to 4 million units 
every 4 to 6 hours. For other MSSA, the penicillinase-resistant penicillins given intravenously 
have traditionally been considered the drug of choice (Lew & Waldvogel 2004).  
 
Vancomycin 
Vancomycin is recommended for the treatment of MRSA osteomyelitis (Lew & Waldvogel 
1997). The use of vancomycin for treatment of osteomyelitis has increased dramatically with 
the emergence of MRSA, which now comprises the majority of S.aureus infections seen in 
hospitals throughout all regions of the United States (Shorr 2007). Retrospective studies have 
demonstrated higher relapse rates after vancomycin compared with those after a β-lactam for 
non-MRSA bone infections (Tice et al. 2003). One consequence of increasing vancomycin 
use is emergence of strains with decreased vancomycin susceptibility (Kollef 2007, Shorr 
2007).  
 
Clindamycin 
Clindamycin is recommended for long-term oral therapy in bone infections with susceptible 
pathogens (Lew & Waldvogel 2004), and because of its activity against anaerobes, 
clindamycin has also been recommended for use in anaerobic bone infections (Brook & Foote 
2005, Bystedt et al. 1978, Darley et al. 2004, Deodhar et al. 1972, Dirks & Terezhalmy 2004, 
Finegold et al. 1977, Trampuz & Zimmerli 2006).  
Clindamycin has excellent bone penetration (Bystedt et al. 1978) and oral 
bioavailability, and performed as well as β-lactam monotherapy in the rabbit osteomyelitis 
model. It has been used successfully for S. aureus osteomyelitis in both children and adults 
(Kaplan et al. 1982, Norden et al. 1986, Rodriguez et al. 1977). However, it is difficult to 
interpret results for clindamycin, as the available studies are quite old. Most bone penetration 
studies of clindamycin were conducted in the 1970s (Landersdorfer et al. 2009).  
In summary, the results of studies of clindamycin suggest similar or slightly higher 
penetration compared with β-lactams (Landersdorfer et al. 2009). These studies only 
compared clindamycin with the other drugs that were available at the time, before the 
development of comparably newer antibiotics such as the quinolones, linezolid and 
azithromycin, which all show high tissue penetration (Landersdorfer et al. 2009). Concerns 
about an association with pseudomembranous colitis have limited its use in elderly patients as 
well (Darley et al. 2004). 
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Linezolid   
Several newer agents with good in vitro and in vivo activity against MRSA have recently 
been introduced (Lovering et al. 2002). One of the best studied of these is linezolid (Lovering 
et al. 2002). Linezolid is a synthetic antibiotic belonging to a new class of antimicrobials 
called the oxazolidinones (Ament et al. 2002). Linezolid is active against S.aureus including 
nearly all MRSA strains, and it has nearly 100 % oral bioavailability and demonstrates good 
bone penetration (Lovering et al. 2002).  
Linezolid disrupts bacterial growth by inhibiting the initiation process in protein 
synthesis. This site of inhibition occurs earlier in the initiation process than other protein 
synthesis inhibitors (e.g. chloramphenicol, clindamycin, aminoglycosides, macrolides) that 
interfere with the elongation process (Ament et al. 2002). Because the site of inhibition is 
unique to linezolid, cross-resistance to other protein synthesis inhibitors has not yet been 
reported (Ament et al. 2002, Ford et al. 1997, Hamel et al. 2000).  
 Successful treatment of osteomyelitis patients with linezolid has been reported 
(Rayner et al. 2004). However, clinical experience in osteomyelitis is limited (Lew & 
Waldvogel 1997). Although the clinical studies show promising results with Linezolid, the 
side effects outweigh the positive features. Serious toxicities reported with prolonged 
linezolid therapy include lactic acidosis, syndromes, optic neuritis and peripheral neuropathy 
(Falagas et al. 2007, Sennevill et al. 2006). Thus, Linezolid is not an ideal agent for very 
prolonged treatment courses or chronic suppurative therapy (Fraimow 2007).  
 
Cephalosporins 
In 1982, Daly et al. (1982) performed a study where the ability of cefazolin to cross capillary 
membranes was studied in normal and osteomyelitic canine bone. These studies suggest that 
the altered pathophysiology of osteomyelitic tissue and the complex diffusional characteristics 
of cefazolin enhanced the ability of this agent to cross the endothelial cells lining the 
capillaries of osteomyelitic bone.  
Pinto et al. (1986) conducted a study where the bone penetration of ceftazidine was 
recorded in cortical and cancellous bone. The results were promising in both infected and 
non-infected bone. Similar results have been published for cefonicid, and the drug has been 
recommended in the treatment of osteomyelitis (Pontzer & kaye 1984). Wittmann & Schassan 
(1980) reported good cefotaxime concentration in infected bone tissue. 
 The first-generation cephalosporin, cefadroxil, has been shown to have a wide 
spectrum of activity against both aerobic and anaerobic bacteria, which may be of importance 
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in orofacial infections (Cumming et al. 1984). Cumming et al. (1984) conducted a study, 
where the purpose was to evaluate the role of cefadroxil in the management of patients 
presenting with acute orofacial infections. The results of this study showed that the MICs of 
cefadroxil for all of the bacteria recovered, were within attainable blood levels.  
On the basis of the results presented in this clinical trial, the authors suggested that 
cefadroxil may be included in the list of possible drugs used in the treatment of acute 
orofacial infections (Cumming et al. 1984). Third- and fourth-generation cephalosporins have 
also been used for MSSA infections, though this must be weighed against the impact of their 
broader spectrum of action and suppression of normal host bacterial flora and impact on 
resistance (Fitzgerald 1984, Fraimow 2009).  
 
Fluoroquinolones 
Quinolones have been the center of considerable clinical and scientific interest since their 
discovery in the early 1960s (Ball 2000). This is because they potentially offer many of the 
attributes of an ideal antibiotic, combining high potency, a broad spectrum of activity, good 
bioavailability, oral and intravenous formulations, and a large volume of distribution 
indicating concentration in tissues (Andersson & MacGowan 2003, Núñez et al. 2009, Stein 
1996).  
They possess several properties that enable them to distribute rapidly into tissues, 
namely, a relatively small molecular size, lipid solubility, long serum half-life, and low levels 
of binding to serum proteins (Gerding & Hitt 1989, Stein 1996).  
 The fluoroquinolones are established agents in the treatment of osteomyelitis (Lew & 
Waldvogel 1999, Mader et al. 1999). Most published data are for ciprofloxacin and ofloxacin, 
though there is clinical experience with newer agents as well (Gerding & Hitt 1989, Lazzerini 
et al. 2005, Rissing 1997, Stengel et al. 2001). The data for ofloxacin and pefloxacin are 
limited but suggest that their penetration into bone is excellent (Gerding & Hitt 1989). 
 Moxifloxacin is a relatively new fluoroquinolone with a broad antimicrobial spectrum 
and improved activity against Gram-positive microorganisms and anaerobes (Blondeau 1999, 
Fass 1997, Hoogkamp-Korstanjie & Roelofs-Willemse 2000, Malathum et al. 1999, 
Malincarne et al. 2006, Nord 1996). It also shows an enhanced potency against both 
methicillin-susceptible and –resistant isolates of S.aureus (Al-Nawas & Shah 1998, 
Krasemann et al. 2001, Lister 2001, Schmitz et al. 1998, Speciale et al. 2002, von Eiff & 
Peters 1999). 
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One study performed by Cachovan et al. (2009) investigated the levels of moxifloxacin in 
mandibular bone in rats. The results showed that moxifloxacin has good penetration into bone 
and muscle tissues in rats, indicating that this agent might be an option for clinical application 
(Cachovan et al. 2009).  
Another study on the penetration properties of moxifloxacin was performed by 
Malincarne et al. (2006). The results from this study also showed a good penetration of 
moxifloxacin into both cancellous and cortical bone.  
 In addition to their high concentrations in bone, the fluoroquinolones ability to 
penetrate into cells may be advantageous in bone infections, as S.aureus has been shown in 
vitro to penetrate into and survive in bone cells (Hudson et al. 1995, Jevon et al. 1999). 
Quinolones have an effect on adherent bacteria, and they can penetrate macrophages and 
polymorphs (Hooper & Wood 1991). 
 There are several excellent reviews of trials of quinolone in bone infections, which 
summarize encouraging results in studies including Gram-positive, Gram-negative and 
polymicrobial infections (Giammarellou et al. 1995, Lew & Waldvogel 1997, Oliphant & 
Green 2002, Rissing et al. 1997, Trichilis et al. 2000). However, there are some 
negative aspects associated with the use of quinolones. To my knowledge, there are no long-
term follow-up data are available when it comes to treating osteomyelitis with 
fluoroquinolones.  
One concern is the adverse effects associated with fluoroquinolones, including central 
nervous system disorders, photosensitivity, hepatic dysfunction, and rashes (Committee of 
Infectious Diseases 2006, Oliphant & Green 2002).  
Another major concern with fluoroquinolones, as with other antimicrobial drugs, is 
emergence of resistance on therapy (Committee on Infectious Diseases 2006). Increasing 
resistance amongst S.aureus has been observed since the introduction of quinolones 
(Blumberg et al. 1991), and has resulted in the addition of rifampicin to attempt to prevent 
this occurring during treatment (Darley et al. 2004, Norden 1975, Yourassowksy et al. 1981, 
Zinner et al. 1981).  
 
Conclusion  
In the treatment of infections, it is evident that adequate antibiotic concentration must be 
obtained at the site of the infection (Bystedt et al. 1978). Successful treatment of osteomyelitis 
in the jaws presupposes that concentrations of an antibiotic exceeding the minimum inhibitory 
concentration (MIC) of microorganisms causing the infection are achieved (Bystedt et al. 
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1978). In addition to good bone penetration, an antimicrobial agent needs to have adequate 
activity against the infecting pathogen, and both the pharmacokinetic characteristics of the 
drug and the anatomical characteristics of the infection sites must be taken into account in 
order to avoid drug underexposure in the bone (Navarro 2009, Pea 2009).  
 The diffusion rate of antibiotics into dead bone is sometimes so low that frequently it 
is difficult to reach the organisms regardless of the external concentration (Hasegawa et al. 
2003). This may lead to ineffective antibiotic concentrations at the site of infection despite 
serum levels indication therapeutic concentration (Prasad et al. 2007).  
 The presence of increasingly resistant microorganisms is a concern, both in terms of 
managing the affected patient and the wider cross-infection implications. The increased 
frequency of antibiotic usage as well as wider variety of antibiotics has resulted in the 
emergence of resistant organisms, often to multiple antibiotics (Prasad et al. 2007). These are 
some of the challenges that clinicians have to face. It is therefore important that the dental 
clinician keep pace with new knowledge concomitantly with maintenance of basic 
comprehension, and make correct assessment if the condition requires medical referral. 
 
4. Antimicrobial therapy and sinusitis  
 
Pathophysiology of sinusitis 
Sinusitis generally develops as a complication of viral or allergic inflammation of the upper 
respiratory tract. Edema and mucosal thickening can lead to inadequate drainage of the sinus. 
This produces stagnation of secretions, pH changes, epithelial damage and reduced oxygen 
tension, which creates an ideal environment for bacterial growth. The resultant bacterial 
products retained within the sinus then cause more mucosal thickening, alteration in the 
cellular architecture and ciliary dysfunction, which may establish a pathogenic cycle of 
chronic infection (Revonta & Blokmanis 1994). 
 The most common precursors to sinusitis include bacterial infections, viral upper 
respiratory infection, sinus obstruction from mucosal edema of inhalant allergies, and 
anatomic factors such as septal deviations (Anon et al. 2004, Hadley & Schaefer 1997, 
Kaliner et al. 1997).  
Maxillary sinusitis of odontogenic origin may result from periapical infection, 
periodontal disease, perforation of the antral floor and mucosa with tooth extraction, and 
displacement of root or foreign objects into the maxillary sinus during a dental or surgical 
procedure (Abrahams et al. 1996, Anon et al. 2004, Heath 1972).  
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Microbiology of sinusitis 
Most cases of sinusitis are thought to be of bacterial etiology (Pynn & Nish 2008). As with 
odontogenic infections, sinusitis is most often polymicrobial and mixed aerobic/anaerobic in 
nature (Pynn & Nish 2008). The most common bacterial species isolated from patients with 
acute sinusitis are Streptococcus pneumonia, Haemophilus influenza and Moraxella 
catarrhalis (Anon et al. 2004, Berg et al. 1996, Blustone et al. 1996, Brook 2005, Gwaltney & 
Sydnor 1981, Hamory et al. 1979, Haye et al. 1996, Sandler et al. 1996, Tristam et al. 2007, 
Wald et al. 1984). These are all facultative aerobic bacteria (Brook 2005).  
Other bacterial isolates found in patients with sinusitis include Streptococcus 
pyogenes, Staphylococcus aureus and anaerobes (Berg et al. 1996, Blustone et al. 1996, 
Brook 2003, Gwaltney & Sydnor 1981, Wald et al. 1984).  
Anaerobic bacteria emerge as pathogens as the infection becomes chronic (Brook 2005, Evans 
et al. 1975, Hamory et al. 1979). S.aureus and anaerobic bacteria such as Prevotella spp., 
Porphyromonas spp. and Fusobacterium spp., are also commonly isolated in chronic sinusitis 
(Brook 2005, Evans et al. 1975, Vakharia et al. 2009).  
 In chronic sinusitis the etiologic infectious organisms are highly variable, with 
anaerobic organisms isolated with increased frequency. Brook (1981) reported that 88 % of 
culture positive cases in sinus infections contained anaerobes, and 32 % were part of a mixed 
infection. Of the anaerobes approximately 50 % exhibited  -lactamase activity.  
 
Clinical presentation 
It is important to accurately diagnose the type of sinusitis a patient has before initiating 
treatment, as the bacteriology and management of each condition differs significantly. Patient 
evaluation should start with a thorough history and complete local examination (Pynn & Nish 
2008).  
Acute sinusitis presents with rhinorrhea that often is purulent, unilateral or bilateral 
infraorbital tenderness, nasal obstruction, dull headache, intermittent fever, and/or cheek 
swelling of less than 3 weeks duration (Stankiewicz et al. 1994). Additional signs can include 
tenderness with chewing, halitosis, and altered sense of smell or taste (Stafford 1990). 
Chronic sinusitis is defined as signs and symptoms of sinusitis which persist for more than 12 
weeks (Stankiewicz et al. 1994). 
 The close proximity of the maxillary sinus floor to the root apices of the posterior 
maxillary teeth may lead to symptoms that suggest dental diseases (Kennedy 1990). Sinus 
infections of odontogenic origin can be differentiated from infections arising secondary to 
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upper respiratory tract infections based on the difference in presentation and microbiology 
(Sandler et al. 1996). This type of sinusitis represents approximately 10 % of all cases (Brook 
2005, Maloney & Doku 1968).  
Inflammation of the sinus lining can produce percussion sensitivity in the molar teeth. 
However, in the absence of concurrent pulpal disease these teeth will respond vital to pulp 
testing and will not exhibit thermal sensitivity (Pynn & Nish 2008). In addition, pain that 
varies with changes in head position is suggestive of sinusitis (Pynn & Nish 2008).  
X-ray of the sinuses may be taken to evaluate symptoms of possible sinusitis. An OPG 
is commonly used to help distinguish uncomplicated sinusitis from other problems that may 
cause similar symptoms, such as odontogenic infections or jaw joints. However, if sinusitis is 
suspected and other possible causes are eliminated, computed tomography (CT) scan shows a 
much clearer picture of the sinuses (Sinus X-ray for Sinusitis).  
 
Management of sinusitis 
The management goals for the treatment of sinusitis include control of infection and pain, 
reduction of tissue edema and facilitation of drainage (Pynn & Nish 2008). When selecting 
antibiotic therapy for patients with sinusitis, the clinician should consider the severity of the 
disease, the rate of progression of the disease, and recent antibiotic exposure (Anon et al. 
2004). The goal of antimicrobial therapy is to eradicate susceptible organisms in the sinus 
cavity (Brook & Foote 2005), and to facilitate recovery and prevent septic complications 
(Brook et al. 2008). 
 The growing resistance to antimicrobial agents of all respiratory tract bacterial 
pathogens has made the management of sinusitis more difficult (Brook & Foote 2005). 
Additionally, factors within the sinus cavity that may enable organisms to survive 
antimicrobial therapy are: inadequate penetration of antimicrobial agents, a high protein 
concentration (can bind antimicrobial agents), a high content of enzymes that inactivate 
antimicrobial agents (i.e. β-lactamase), decreased multiplication rate of organisms that 
interfere with the activity of bacteriostatic agents and reduction in pH and oxygen partial 
pressure, which reduces the efficacy of some antimicrobial agents (e.g. aminoglycosides and 
fluoroquinolones) (Brook & Foote 2005). 
 Some antimicrobials have a narrow spectrum of activity. For example, metronidazole 
is only effective against most anaerobes and therefore cannot be administered as a single 
agent for the therapy of mixed infections, which, as stated above, sinusitis is. The low pH and 
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the anaerobic environment are also unfavorable for the aminoglycosides and fluoroquinolones 
(Brook 2006). 
 
Results from studies on the use of different antibiotics in treating sinusitis  
Penicillin 
Amoxicillin therapy is considered to be the first-line of treatment for acute bacterial sinusitis 
(Brook 2005, Hamory et al. 1979, Mehra & Jeong 2009, Pynn & Nish 2008). Amoxicillin is 
relatively safe and well tolerated. Given its intrinsic activity and excellent bioavailability, 
amoxicillin is generally considered the most active of all oral β-lactams against streptococci, 
including S. pneumoniae. The addition of clavulanic acid to amoxicillin does preserve the 
activity of the agent in the presence of β-lactamases (Anon et al. 2004).  
 
Macrolides  
These agents are active against Gram-positive and some Gram-negative bacteria. Although 
they are generally considered to be bacteriostatic, they are bactericidal against autolytic 
species such as pneumococci (Anon et al. 2004).  
Macrolides exhibit better antimicrobial activity in an environment with neutral to basic pH. 
This physicochemical characteristic is due to the fact that at low pH macrolides become 
positively charged and do not readily cross biological membranes (Anon et al. 2004).  
Additionally, the increasing prevalence of macrolide resistance to S.pneumoniae is 
associated with a significant likelihood of clinical failure (Dagan et al. 2000, Haye et al. 
1996). Cross-resistance of S. pneumoniae is also common among all macrolides (Brook 
2005).  
 
Cephalosporins 
The physicochemical properties of many oral cephalosporins make them less suitable than 
penicillin/amoxicillin when S. pneumoniae is the infecting pathogen. Cephalosporins are 
inherently less active than penicillin/amoxicillin against S. pneumoniae. First-generation 
cephalosporins lack sufficient efficacy against H. influenzae and many S. pneumoniae strains 
(Brook et al. 2005).  
Third-generation cephalosporins are most effective against penicillin-resistant 
Haemophilus and Moraxella spp., but they are less effective against S.pneumoniae resistant to 
penicillin (Brook 2004). Furthermore, cephalosporins are actively absorbed in the 
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gastrointestinal tract, which limits the concentration that can be achieved, regardless of the 
magnitude of dose administered (Anon et al. 2004). 
 
Clindamycin 
Clindamycin has good efficacy against aerobic Gram-positive organisms. It is not however, 
active against H. influenzae and M. catarrhalis (Anon et al. 2004). 
 
Fluoroquinolones 
The older quinolones (i.e. ciprofloxacin, ofloxacin) are effective against H. influenzae and M. 
catarrhalis, but have minimal activity against S. pneumoniae (Brook et al. 2005). The newer 
quinolones (e.g. moxifloxacin, levofloxacin) have improved activity against S.pneumoniae 
(Brook et al. 2005).  
The predominant concern surrounding fluoroquinolone use pertains to the selection of 
class resistance in organisms such as Gram-negatives, staphylococci and pneumococci (Anon 
et al. 2004). As with most agents, development of resistance among S.pneumoniae strains to 
one fluoroquinolone generally leads to cross-resistance to all members of the fluoroquinolone 
class, and there is evidence that inappropriate use is linked to the development of resistance 
and to clinical failures (Kays et al. 2002, Kuehnert et al. 1999, Ross et al. 2002, Urban et al. 
2001). Because of this, fluoroquinolones should not be used indiscriminately (Anon et al. 
2004). These agents are currently not recommended for use in children either, because of the 
potential adverse effects on the cartilage (Brook et al. 2005). 
 
Are dentists supposed to treat patients with sinusitis? 
Sinusitis is a relatively common disease. Even so, sinus infections are among the most 
frequently misdiagnosed and misunderstood diseases in clinical practice. The dental clinician 
must be aware of the various diseases of the sinuses and their possible presentations. In the 
dental office, both acute and chronic sinusitis of non-odontogenic origin may present as 
chronic orofacial pain or atypical pain from dental origin, and will require appropriate 
medical referral. To determine appropriate care for a patient presenting with sinusitis 
symptoms, the dental clinician must understand the anatomy, pathophysiology and 
microbiology of the sinuses (Pynn & Nish 2008) and be able to diagnose the condition 
correctly. 
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Conclusion  
Antimicrobials used for chronic sinusitis therapy should be effective against both aerobic and 
anaerobic microorganisms. But, controversies exist regarding the need to provide coverage 
against all bacterial isolates as some studies of the treatment of acute maxillary sinusitis 
suggested that utilization of narrow spectrum antimicrobials were as effective as wide 
spectrum ones (Lindbaek et al. 2004, Lindbaek et al. 2007). 
Recent studies of acute sinusitis have also questioned the value of antibiotic treatment, 
reporting little improvement in symptom resolution when comparing antibiotics versus 
placebo (Merenstein et al. 2005, Williamson et al. 2007, Young et al. 2008). Most patients 
with acute sinusitis improve within 2 weeks without antibiotics. The potential risk of adverse 
effects from antibiotics may also outweigh the benefits of therapy (Baily et al. 2009). 
 However, patients that do receive antibiotic because of signs of systemic involvement 
must be monitored carefully with respect to efficacy of the agent and improvement of the 
symptoms. The current recommended duration of treatment when treating acute sinusitis is 
10-14 days. Failure to respond to antimicrobial therapy after 3 days should prompt either a 
switch to alternative antimicrobial therapy or reevaluation of the patient (Anon et al. 2004). 
The length of therapy when treating chronic sinusitis is at least 21 days, and may be extended 
up to 3 month. In addition to medical therapy, surgical drainage must be considered when 
dealing with chronic sinusitis (Brook 2009).  
The dental clinician’s job is to diagnose the condition correctly and refer the patient to 
his/her physician immediately. 
 
5. Antimicrobial therapy and tonsillitis  
 
Tonsillitis is an inflammation of the tonsils most commonly caused by viral or bacterial 
infection (Brook 2003, Brook 2005).  
 
Microbiology of tonsillitis 
Tonsillitis is most often polymicrobial (Kilty & Desrosiers 2008, Rajasou et al. 1996). 
Common bacterial pathogens include Group A beta-hemolytic streptococci and other 
streptococci (Brook 2003). Tonsillitis may result from infection with bacteria or viruses. Viral 
causes include adenovirus, infectious mononucleosis from Epstein-Barr virus infection, 
cytomegalovirus, HIV, hepatitis A, and rubella (Georgalas et al. 2009, Wyndham 2008).  
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Dias et al. (2009) conducted a study where the purpose was to characterize the association 
between Epstein-Barr virus and recurrent tonsillitis. The results showed that children’s tonsils 
can be colonized by EBV and such colonies may be associated with the pathogenesis of 
recurrent tonsillitis (Dias et al. 2009). 
 
Clinical presentation 
Common symptoms are sore throat and difficulty with swallowing (Wyndham 2008). Other 
accompanying symptoms include fever, red and/or swollen tonsils, white or yellow areas on 
the tonsils, halitosis, stiff neck, lymphadenopathy, cough, and headaches (Brook 2003, 
Wyndham 2008). 
 
The role of antimicrobial therapy in the treatment of tonsillitis 
Bacterial tonsillitis is treatable with antibiotics. Antimicrobial therapy is considered if there 
are signs of systemic involvement, such as fever, lymphadenopathy, and difficulty in 
swallowing. Tonsillectomy is considered for those who have 5 or more episodes in a year 
(Wyndham 2008). 
 The main purpose of treating acute tonsillitis cases with antibiotics is to reduce the 
possibility of suppurative and non-suppurative complications associated with Group A beta-
hemolytic streptococci (Sih & Bricks 2008). 
 
Results from studies on the use of different antibiotics in treating tonsillitis 
 
Penicillin 
Even though antibiotics other than penicillin are more effective in the cure of Group A beta-
hemolytic streptococci tonsillitis, penicillin is still recommended in some guidelines as the 
antibiotics of choice (Brook 2001, Brook 2007). But, the growing inability of penicillin to 
eradicate Group A beta-hemolytic streptococci (GABHS) which leads to clinical and 
bacteriological failures is an important clinical problem (Brook 2009), and should be taken 
into consideration. 
Various theories explain this penicillin failure that may lead to recurrent tonsillitis 
(Brook 1984). These explanations include bacterial interactions between GABHS and 
members of the tonsillar microflora. One theory is that β-lactamase producing bacteria can 
shield GABHS by inactivating penicillin (Brook 2005).  
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Another explanation is that interfering organisms such as alpha-streptococci that are 
part of the normal oral flora, are missing in many of those patients who fail penicillin therapy 
(Crowe et al. 1973, Sanders 1969, Sanders et al. 1976, 1977). These alpha-streptococci play 
an important protective role in preventing colonization and subsequent infection by Group A 
beta-hemolytic streptococci, and their absence may lead to failure of penicillin therapy 
(Sanders et al. 1969).  
 
Several studies have shown that alpha-streptococci can inhibit the colonization of a variety of 
pathogens such as S.pneumoniae, GABHS, and S.aureus in patients as well as in vitro (Aly et 
al. 1974, Crowe et al. 1973, Johanson et al. 1970, Sanders 1969). Their production of 
bacteriocin and other inhibitory substances may explain this phenomenon.  
Suppression of some bacterial growth may also occur through utilization of nutrients 
in the nasopharyngeal environment essential for the colonization by potential pathogens (Roos 
et al. 1989).  
Eradication failure might be due to the lack of sufficient antibiotic concentration at the 
site of infection during the recommended treatment time. Some studies identified this 
phenomenon as a possible mechanism of phenoxymethylpenicillin treatment failures (Holm & 
Ekedahl 1982, Kaplan et al. 1974, Roos et al. 1986, Stjernquist et al. 1993, Strömberg et al. 
1987, Sundberg et al. 1982). 
Patients who fail penicillin therapy may respond to treatment effective against beta-lactamase 
producing bacteria,
 
such as amoxicillin-clavulanate (Pichichero & Casey 2007).  
 
Cephalosporins 
The success rate of eradication of Group A beta-hemolytic streptococci in acute tonsillitis is 
higher with cephalosporins than with penicillins (Brook 2005, Casey et al. 2004). The 
cephalosporins increased efficacy may be due to their activity against aerobic β-lactamase 
producing bacterial such as S.aureus, Haemophilus spp. and M.catarrhalis.  
Another possible reason is that the non-pathogenic interfering aerobic and anaerobic 
bacteria which compete with GABHS (Brook 2005), are more resistant to cephalosporins than 
to penicillin and are therefore more likely to survive cephalosporin therapy (Brook 2004). 
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Macrolides 
Macrolides are also an alternative choice therapy of tonsillitis (Brook 2009). O’Doherty et al. 
(1996) compared the efficacy and safety of azithromycin and penicillin V in the treatment of 
acute streptococcal pharyngitis/tonsillitis in pediatric patients. A total of 489 children were 
randomized into 3 test-groups: (1) Penicillin V 125-250 mg 4 x daily for 10 days, (2) 
Azithromycin 10 mg/kg 1 x daily for 3 days, (3) Azithromycin 20 mg/kg 1 x daily for 3 days. 
A satisfactory clinical response was recorded in all 3 test-groups. The authors concluded that 
azithromycin was as safe and effective as penicillin V in the treatment of acute 
pharyngitis/tonsillitis. 
However, their increased use has been associated with increased Group A beta-
hemolytic streptococci resistance (Urbanek et al. 2004). Resistance of Group A beta-
hemolytic streptococci to macrolides reached up to 70 % in Finland, Italy, Japan and Turkey 
(Colakoglu et al. 2006). In the United States, the current resistance is 6-16 % (Richter et al. 
2005). Clinicians therefore advise to avoid the routine use of macrolides for Group A beta-
hemolytic streptococci tonsillitis and reserve them for those with penicillin allergy (Brook 
2009).  
 
Metronidazole 
Therapy with metronidazole relieved the symptoms of tonsillar hypertrophy and shortened the 
duration of fever in patients with infectious mononucleosis (Hedström et al. 1978). Because 
metronidazole has no antiviral or antiaerobic bacterial activity, suppression of the oral 
anaerobic flora may explain its clinical effects. It has been suggested that this microflora may 
act synergistically with the Epstein-Barr virus (Hedström et al. 1978). This explanation is 
supported by the increased recovery of P.intermedia and F.nucleatum during the acute phases 
of infectious mononucleosis (Brook 1992). 
 
Fluoroquinolones 
There are very few studies were the tonsillar tissue concentration of fluoroquinolones has 
been investigated. In one such study, the moxifloxacin concentration in plasma and tonsillar 
tissue was determined (Esposito et al. 2006). The authors concluded that moxifloxacin 
achieves good penetration in tonsillar tissue, but long-term follow-up data on these agents are 
not yet available. 
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Conclusion 
Taking into account the difficulty of penicillin to penetrate the tonsillar tissue, the increasing 
macrolide resistance among streptococcal strains, and the changing epidemiology of 
pharyngotonsillitis etiology, it is clear that the management of tonsillitis is challenging.  
Overuse and inappropriate use of antibiotics has led to the emergence of bacterial 
resistance, in addition to exposure to unnecessary side effects (Ayyad et al. 2009). 
Additionally, misuse of antibiotic therapy and thereby changes to the tonsillar microflora, and 
viral infections have also been listed as predisposing factors for recurrent tonsillitis (Dias et 
al. 2009). 
 The dental clinician must be aware of the various signs and symptoms of tonsillitis, in 
order to be able to determine appropriate care for a patient presenting with tonsillitis 
symptoms. Diagnosis of acute tonsillitis is primarily clinical, with the main interest being 
whether the illness is viral or bacterial - this being of relevance if antibiotics are being 
considered (Georgalas et al. 2009). Studies have attempted to distinguish viral from bacterial 
tonsillitis on clinical grounds, but the results are conflicting, suggesting a lack of reliable 
diagnostic criteria. It has been estimated that 75 % of tonsillitis cases in children are caused 
by viruses; however, most of these cases are treated with antibiotics (Bricks 2003, Del Mar et 
al. 2006, Sih & Bricks 2008).  
Antimicrobial therapy must be considered only if there are signs of systemic 
involvement, such as fever, lymphadenopathy, and difficulty in swallowing. The condition 
must be correctly diagnosed, and the patient must be referred to his/her physician 
immediately.  
 
6. Antimicrobial therapy and sialadenitis 
 
What is sialadenitis? 
Sialadenitis is an infection of the salivary glands (Sialadenitis 2011). It can occur in any of the 
glands, and can present as an acute single episode or as multiple recurrent episodes (Brook 
2009, Sialadenitis 2011). The parotid gland is the salivary gland most commonly affected by 
inflammation (Brook 2007). The parotid gland is almost purely a serous gland and is therefore 
highly susceptible to infection secondary to stasis. In contrast, the increased mucus 
concentration within sublingual and submandibular gland gives bacteriostatic protection 
(Magilner & Amburgey 2008).  
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Clinical features of sialadenitis are typically an enlarged, tender or a red salivary gland 
(Sialadenitis 2011). Other symptoms may be difficulty in opening the mouth, fever, or 
swelling of the lymph nodes in the neck region (Sialadenitis 2011, What is Sialadenitis? 
2011). 
Sialadenitis may be classified as acute or chronic, and may be bacterial, viral, fungal, 
mycobacterial or parasitic (Carlson 2009). An acute sialadenitis may be diagnosed when 
symptoms have existed less than 1 month, while a chronic condition is considered when 
symptoms are greater than 1 month in duration (Carlson 2009, Mandel & Witek 2001, Patel & 
Karlis 2009, Yu et al. 2007).  
The dental clinician has to be aware that a chronic sialadenitis most often is secondary 
to sialolithiasis. Sialolithiasis is the formation of stones in a salivary gland or duct 
(Primehealthchannel 2011). Diagnosis of salivary gland stones are done by medical history 
and physical examination. Common sialolithiasis symptoms include swelling and discomfort 
in the affected salivary gland. Since chewing promotes release of saliva, symptoms tend to 
exacerbate during meals. Confirmation of sialolithiasis can be done by X-rays. 
(Intelligentdental 2011). 
 
Microbiology sialadenitis 
Viruses are the most common causes of parotitis in children (Brook 2003, Brook 2007, Brook 
2009), including paramyxovirus (mumps), HIV, Epstein-Barr virus, coxsackievirus, 
parainfluenza virus, influenza virus, and cytomegalovirus (Brook 2003).  
S. aureus has long been recognized as a common cause of suppurative parotid gland 
infection in adults (Brook 2003, Enoch et al. 2003). S. aureus, Streptococcus pyogenes, and 
rarely, aerobic Gram-negative bacteria are the predominant isolates from acute suppurative 
parotitis (Brook 2003, Brook 2007, Brook 2009, Echevvarria et al. 1987, Fordyce 1996, 
Giglio et al. 1997, Kaban et al. 1978, Krippaehne et al. 1962, Raad et al. 1990). 
 
Clinical presentation 
Acute suppurative parotitis occurs mostly in children younger than 2 months of age and in 
elderly patients who are debilitated by systemic illness; although persons of all ages may be 
affected (Brook 1992, Krippaehne et al. 1962). Other predisposing factors include 
dehydration, immunosuppression, malnutrition, poor oral hygiene, trauma, neoplasms of the 
oral cavity, ductal obstruction and medications that diminish salivary flow (Echevvarria et al. 
1987, Fordyce & Stassen 1996, Krippaehne et al. 1962). It is evident that the clinician should, 
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if possible, reverse such conditions during the acute phase of the sialadenitis to prevent spread 
of infection or the development of a chronic sialadenitis (Carlson 2009). Correct diagnose is 
crucial, and the dental clinician need to refer the patient to his/her physician as soon as 
possible, to avoid Doctor’s delay.  
 
The role of antimicrobial therapy in the treatment of sialadenitis 
As mentioned above, the initial evaluation of a patient with a salivary gland swelling must 
begin with a comprehensive history and examination. Therapy includes maintenance of 
hydration and administration of oral or parenteral antimicrobials. Once an abscess has formed, 
drainage is required.  
Maintenance of good oral hygiene, adequate hydration and early and proper therapy of 
bacterial infection is crucial (Antoniades & Harrison 2004, Brook 2007).  
 The choice of antibiotic depends on the etiologic agent. Most patients respond to 
antimicrobial therapy; however, some inflamed glands my reach a stage of abscess formation 
that requires surgical drainage immediately (Brook 2007). In bacterial sialadenitis, antibiotic 
selection should reflect the fact that S.aureus is frequently cultured in cases of acute 
suppurative parotitis. The patient needs to be monitored carefully. For cases which do not 
respond over 3 days, an antibiotic change should be considered. 
 Broad antimicrobial coverage is indicated to cover all possible aerobic and anaerobic 
pathogens, including adequate coverage for S. aureus, GABHS, and β-lactamase producing 
bacteria (Brook 2007). Clearly, the greater the magnitude of purulent infection noted on 
physical examination, the greater the likelihood that admission to the hospital and incision 
and drainage will be necessary (Carlson 2009). 
 
When it comes to chronic sialadenitis, antibiotics have been used in treating the exacerbations 
that are so characteristic of the disease. They are effective in controlling the acute attack; but 
are unable to heal the disease or to prevent further recurrent infections (Diamant & Enfors 
1965). This is because the obstruction of the duct in chronic sialadenitis is most often caused 
by sialolithiasis. Therefore, in chronic recurrent sialadenitis, usually surgery is considered 
(Diamant & Enfors 1965, Brook 2003, Brook 2005, Katz et al. 2009), and the patient needs to 
be referred immediately.  
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7. Special topics  
 
7.1 Endocarditis prophylaxis 
Bacterial endocarditis is an infection of either the heart’s inner lining (endocardium) or the 
heart valves (Endocarditis 2011). The term prophylactic antibiotic implies the use of 
antimicrobial agents to prevent infections (Abubaker et al. 2009, Pallasch 2003). Surgical 
procedures in the oral cavity are particularly liable to contamination with the local flora found 
there (Alfter et al. 1995). 
The most common cause of this infection is bacteria (Ito 2006), and Streptococcus 
viridans has been implicated as the most common cause of infective endocarditis (Chopra & 
Kaatz 2010, Maestre et al. 2006, Hills-Smith & Schuman 1983, Endocarditis 2011). The 
antibiotic chosen must therefore target this microorganism. 
The rationale for the use of infective endocarditis prophylaxis is based on the concept 
that if bacteremia, which is a crucial component of the pathogenesis of infective endocarditis, 
is prevented, the sequence of events that lead to formation of a vegetation on previously 
damaged valves can be prevented (Chopra & Kaatz 2010).Infective endocarditis is a life 
threatening disease, and prevention is always better to avoid dreadful complications or death 
(Dhoble et al. 2009).  
When endocarditis prophylaxis is indicated, one should seek the help of current 
treatment guidelines. These guidelines include the American Heart Association (AHA), the 
British Society for Antimicrobial Chemotherapy (BSAC) and the European Society of 
Cardiology (ESC) guidelines. The British Society for Antimicrobial Chemotherapy (BSAC) 
recommends 3 g amoxicillin in adults 1 hour before treatment, and in case of penicillin 
allergy, clindamycin 600 mg 1 hour before dental treatment (Gould et al. 2006).  The 
American Heart Association (AHA) (Embil & Chan 2008, Taubert & Dajani 1998) and the 
European Society of Cardiology (ESC) (Gutiérrez  et al. 2006, Habib et al. 2009), 
recommends a single dose of 2 g amoxicillin in adults 1 hour before dental treatment. If the 
patients has penicillin allergy, 600 mg clindamycin 1 hour before dental treatment is 
recommended (Habib et al. 2009, Taubert & Dajani 1998).  
 Recommended dosage for children is amoxicillin 50 mg/kg (maximum 2 g) 1 hour 
before dental treatment and for children with penicillin allergy clindamycin 20 mg/kg 
(maximum 600 mg) 1 hour before dental treatment (Hills-Smith & Schuman 1983, Planells 
del Pozo et al. 2006). 
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The Norwegian recommendations on endocarditis prophylaxis in dental practice 
currently follow these guidelines from AHA and ESC (Aakhus & Bjørneklett 2008). It is 
therefore important that the dental practitioner follows the recommendations from AHA and 
ESC, and keep up to date on new recommendations when old ones are revised (Taubert & 
Dajani 1998). 
 
7.2 Antimicrobial agent and drug interactions  
A drug interaction is a situation in which a substance affects the activity of another substance 
(Drug interaction 2011). Generally speaking, drug interactions should be avoided. However, 
drug interactions have also been deliberately used, such as co-administering probenecid with 
penicillin (probenecid inhibits the excretion of penicillin, and therefore penicillin persists 
longer when taken simultaneously with probenecid) (Rang & Dale 2007, Drug interaction 
2011).  
Also, combination therapy with two antibiotics is used in special cases to take 
advantage of antibiotic synergism. Antibiotic synergism occurs when the effects of a 
combination of antibiotics is greater than the sum of the effects of the individual antibiotics, 
such as trimethoprim-sulfamethoxazole (Rang & Dale 2007, Drug interaction 2011).  
 
Interaction of antibiotics with medicament substrates of the cytochrome family 
The enzymatic systems involved in the bio-transformation of the majority of the medicaments 
are located in the inner membrane of mitochondria or in the smooth endoplasmatic reticulum 
of the liver, which contains an important group of oxidative enzymes (Cytochrome P450 
2011). This is the location of the cytochrome family of which the P450 cytochrome system is 
prominent (Rang & Dale 2007, Stockley 2002). The CYP3A4 isoform is the most abundant 
cytochrome family in the liver and human intestine. In pharmacological interactions an 
induction or enzymatic inhibition can be produced at the metabolic level (Cytochrome P450). 
 The macrolide antibiotics erythromycin and clarithromycin are potent irreversible 
inhibitors of the CYP3A4 and CYP1A2 isoenzymes, which can significantly increase 
concentrations in blood and toxicity of other medicaments which use this system of 
detoxification (Felleskatalogen 2011, Hersh & Moore 2008). Azithromycin is also a 
macrolide drug. However, this agent is not an inhibitor of the mentioned isoenzymes, which 
makes it a safe alternative in patients who have penicillin allergy and are taking other 
medicaments which could cause problems with erythromycin or clarithromycin 
(Felleskatalogen 2011, Gomez-Moreno et al. 2009).  
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 Ciprofloxacin and erythromycin are inhibitors of the CYP1A2 isoenzymes, which can 
reduce biotransformation and increase blood levels of medicaments which are substrates of 
CYP1A2 such as antihistamines (teofilin), antidepressors (imipramine) and tacrine 
(Felleskatalogen 2011, Hersh & Moore 2008, Stockley 2002, Macrolides 2011, Quinolone 
2011). 
 Metronidazole inhibits CYP2C9, and will give rise to an accumulation of various 
substrates of this isoenzyme (Gomez-Moreno et al. 2009). The CYP2C9 substrates include 
anticoagulants (warfarin), anticonvulsives (fenitoin) and NSAIDs (ibuprofen, naproxen, 
diclophen) (Hersh 1999, Hersh & Moore 2008, Sims & Sims 2007).  
 It is advisable that before prescribing metronidazole to patients undergoing long-term 
treatment with warfarin to consult with the patients physician. As mentioned above; since 
metronidazole is generally used for the anaerobic component of oral infections together with 
penicillin which treats the aerobic, other antibiotics can be used as an alternative for these 
mixed infections, such as clindamycin (Gomez-Moreno et al. 2009).  
 
Interaction of metronidazole with alcohol 
Metronidazole inhibits the activity of the enzyme acetaldehyde dehydrogenase leading to an 
accumulation of acetaldehyde in patients consuming alcohol (Gupta et al. 1970). The reaction 
leads to nauseas, cardiac palpitations and headache (Felleskatalogen 2011). The dentist should 
warn the patients not to drink alcohol during metronidazole treatment for at least 3 days after 
the final treatment (Felleskatalogen 2011, Hersh & Moore 2004). 
 
Interaction of tetracyclines with cations 
Tetracyclines form chelates with polyvalent cations found in the diet, antacids and vitamins 
(Norsk Legemiddelhåndbok 2005). These chelates are insoluble and cannot be absorbed 
through the gastrointestinal tract mucosa and the blood stream and so are excreted (Gomez-
Moreno et al. 2009, Kampmann et al. 2007). Polyvalent cations include calcium, magnesium, 
bismuth, iron, zinc and aluminum (Felleskatalogen 2011, Gomez-Moreno et al.  2009).  
 In these cases it would be prudent that the dentist advise the patient to avoid 
simultaneous ingestion of tetracycline and polyvalent cations (Gomez-Moreno et al. 2009). 
 
Interaction of antibiotics with oral anticoagulants 
Generally, antibiotics alter the normal intestinal flora, especially those that are broad-
spectrum. This flora is important in preventing overgrowth of opportunistic infections in the 
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gastrointestinal tract and is essential for the production and/or absorption of some nutrients, 
vitamins and medicaments (Kampmann et al. 2007, Rang & Dale 2007). Intake of antibiotics 
can lead to less absorption of vitamin K and consequently coagulation factors, VII, IX, and X 
(Sims & Sims 2007). Therefore there is a greater risk of bleeding which is clinically important 
in patients undergoing warfarin treatment over prolonged periods (Gomez-Moreno et al.  
2009).  
 
Interaction of antibiotics with oral contraceptives 
The two components of contraceptive pills, semi-synthetic estrogens and semi-synthetic 
progesterones are CYP3A4 substrates (Hersh & Moore 2008, Stockley 2002). It has been 
shown that rifampicin significantly reduces blood levels of the contraceptive as they are 
potent inducers of the CYP3A4 isoform (Kampmann et al. 2007).  
Therefore, the dentist should warn woman using contraceptives of the possible interaction 
when prescribing antibiotics (Gomez-Moreno et al. 2009). 
 
Interaction of bacteriostatic antibiotics with bactericidal antimicrobial agents 
Since some antimicrobial agents work by interfering with DNA synthesis, it is logical that the 
drugs that are bactericidal would be less effective in a culture whose growth is arrested by a 
bacteriostatic agent. Therefore, it is suggested that bactericidal and bacteriostatic antibiotics 
should not be combined (Gomez-Moreno et al. 2009). 
 
8. Concluding remarks 
The use of antibiotics in dentistry is diverse, and only a selected number of articles on this 
subject have been discussed in this paper. However, despite the great variety of antibiotics, 
some important principles can be summarized from the articles discussed:  
- Patient evaluation should start with a thorough history and examination 
- Antibiotic treatment should be started only if clear indications exist 
- Right diagnosis is crucial for the selection of an appropriate therapy 
- The treatment chosen must be assessed as beneficial for the patient 
- Allergic and toxic reactions must be regarded 
- The potential risk of adverse effects from antibiotics must be weighed against the 
benefits of therapy 
- The selection of antimicrobial agents should be guided by their aerobic and anaerobic 
antibacterial spectrum 
50 
 
- Resistance patterns of the pathogens involved in the infection must be taken into 
account  
 
The selection of antimicrobial agents is simplified when reliable culture results are available. 
However, this may not always be possible because of difficulty obtaining appropriate 
specimens, and the fact that the patient may need emergency treatment. Therefore, many 
patients are treated empirically on the basis of suspected pathogens.  
 Fortunately, the types of microorganisms involved in most odontogenic infections and 
their antimicrobial susceptibility patterns tend to be predictable, although they may vary in 
particular settings. Therefore, it is important that the clinician has knowledge about what type 
of organisms to expect in any type of odontogenic infection, in order to be able to make the 
correct decision about what therapy and/or antibiotic agent to choose.  
The choice of antibacterial agents is also influenced by factors other than 
susceptibility patterns. These include the pharmacokinetic and pharmacodynamic 
characteristics of the various drugs, their toxicity, effect on the normal flora, and 
bacteriostatic/bactericidal activity. 
 The emergence of resistant microorganisms against antibiotics is directly related with 
the excessive use of these drugs (Arnold et al. 2005, Arroll et al. 2005, Moloney & Stassen 
2009). Antibiotic resistance in oral microbes is an issue of concern in general dental practice 
where antibiotics are, in some cases, essential (Al-Haroni et al. 2008, Harrison et al. 1985).  
Antibiotic therapy can also affect the balance between pathogens and normal flora by 
disturbing the ecological balance thus facilitating recurrent odontogenic infections.  
 It has therefore never been more important for us to understand in detail the 
mechanisms of and routes to resistance in pathogenic bacteria, so that we can adjust our 
clinical behavior in ways that minimize the future growth of resistance (Rice 2009).  
Therefore, it is important that the dental clinician keep pace with new knowledge 
concomitantly with maintenance of basic comprehension. 
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